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ABSTRACT 
Antimicrobial-resistant bacteria are a threat to public health worldwide. Particularly, the 
increase of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (EPE) is a 
significant clinical problem. ESBLs confer resistance to cephalosporins and carbapenemases 
confer resistance to carbapenems. Escherichia coli, the most important member of the 
Enterobacterales, is the most common cause of bloodstream infection (BSI). First-line 
treatment is in most cases the cephalosporin cefotaxime, but EPE are resistant to cefotaxime. 
Thus, patients with EPE BSI are at risk of prolonged hospitalization and increased mortality 
caused by empirical treatment failure. This thesis aimed to improve care for patients with 
EPE BSI in three ways: early prediction, rapid diagnosis and increased understanding of 
resistance transmission and the importance of microbial virulence for the severity of disease. 
The aim of Study I was to develop a practical prediction-score to identify patients at risk of 
EPE BSI which could be used to improve the appropriateness of empirical treatment. Risk 
factors for EPE BSI were assessed and two clinical scores evaluated. The strongest predictors 
(named the Stockholm score), prior EPE-positive culture (especially recent samples), prostate 
biopsy and healthcare abroad, were present in 50% of cases. In other patients, prediction was 
difficult, hence rapid diagnostics and susceptibility testing are necessary.  
Therefore, the aim of Study II was to evaluate a method for rapid susceptibility testing. 
EUCAST disk diffusion read after 6 hours was compared to 18 hours on E. coli and 
Klebsiella pneumoniae-isolates representing clinically important resistance mechanisms. 
Results showed that 6-hour reading was accurate if adapted breakpoints were used.   
Resistance traits are mainly spread through clonal expansion of bacterial cells and/or 
horizontal gene transfer trough plasmids. Development of appropriate intervention methods 
depend on knowledge of the mode of transmission. Study III aimed to determine the 
molecular epidemiology of K. pneumoniae harbouring the carbapenemase-gene blaNDM-1. 
Isolates from India, UK and Sweden were subjected to MLST, plasmid replicon typing and 
PCR of virulence genes. Diverse sequence types and plasmids, rather than a single high-risk 
clone, were responsible for the early dissemination of K. pneumoniae with blaNDM-1.  
BSI is often complicated by sepsis and septic shock, associated with high mortality. With 
resistance on the rise, the search for new therapies includes anti-virulence agents. Thus, a 
correct understanding of the influence of microbial virulence on pathogenesis is important. 
The aim of Study IV was to determine the respective contributions of microbial virulence 
and patient factors to the severity of disease. Whole genome sequencing (WGS) was 
performed on E. coli from patients with EPE BSI. The virulence gene iss, increased serum 
survival, was associated with septic shock, especially in immunocompetent patients.   
In conclusion, the treatment of patients with EPE BSI could be improved by these results. 
Use of the Stockholm score identified many, but not all, patients at risk of EPE BSI, thereby 
improving the appropriateness of empirical therapy. Rapid disk diffusion with adapted 
breakpoints gave accurate results and would enable early correction of therapy. blaNDM-1 was 
found in diverse sequence types of K. pneumoniae. The virulence gene iss was associated 
with septic shock in EPE BSI and might have potential as an anti-virulence treatment target.    
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LIST OF ABBREVIATIONS 
AMR Antimicrobial resistance 
APEC Avian pathogenic E. coli (ExPEC subtype) 
AST Antimicrobial susceptibility testing 
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BLAST Basic local alignment search tool 
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BSI Bloodstream infection 
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CTX-M Cefotaxime-Munich β-lactamase. Common group of ESBL-enzymes.  
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EARS-Net European Antimicrobial Resistance Surveillance Network 
EHEC Enterohaemorrhagic E. coli 
EIEC Enteroinvasive E. coli   
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EPEC Enteropathogenic E. coli  
ESBL Extended spectrum β-lactamase 
ESBL-EC ESBL-producing E. coli 
EUCAST European Committee on Antimicrobial Susceptibility Testing 
ExPEC Extra-intestinal pathogenic E. coli  
FDA United States of America Food and Drug Administration 
GLASS Global Antimicrobial Resistance Surveillance System 
Hier CC Hierarchical clustering of cgMLST 
ICU Intensive care unit 
ISO International Organization for Standardization 
KPC K. pneumoniae carbapenemase 
MALDI-TOF MS Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry 
MBL Metallo-β-lactamase 
MDR Multidrug-resistant 
ME Major error 
mE Minor error 
MIC Minimum inhibitory concentration 
MLST Multilocus sequence typing 
  
MRSA Methicillin-resistant Staphylococcus aureus 
NDM New Delhi metallo-β-lactamase 
NGS Next-generation sequencing 
NMEC Neonatal meningitis-associated E. coli (ExPEC subtype) 
NPV Negative predictive value 
OR Odds ratio 
OXA Oxacillinase 
OXA-48 Carbapenem-hydrolysing class D enzyme.  
A group of oxacillinase-related enzymes with carbapenemase-activity. 
PBP Penicillin-binding protein 
PCR Polymerase chain reaction 
PFGE Pulsed-field gel electrophoresis 
PPV Positive predictive value 
rep-PCR Automated repetitive sequence-based PCR 
ROC Receiver operating characteristic 
SIR Susceptibility categories. EUCAST definition:  
S= Susceptible, I= Susceptible, Increased exposure, R= Resistant 
SNP Single nucleotide polymorphism 
SOFA Sequential (sepsis-related) organ failure assessment score 
ST Sequence type (MLST-derived) 
TLA Total laboratory automation 
UPEC Uropathogenic E. coli (ExPEC subtype) 
UTI Urinary tract infection 
VIM Verona integron-encoded metallo-β-lactamase 
VME Very major error 
WCA Work cell automation 
WGS Whole genome sequencing 
3GC Third generation cephalosporin 
3GCR Third generation cephalosporin-resistant  
(mainly caused by ESBL-production) 
A note on terminology:  
In general, the names of genes are composed of a three-four letter code, always italicized. 
The name of the protein product is capitalized with variants of the genes identified with a 
serial number based on the order of first observation. Thus blaNDM-1 and blaCTX-M-15 refers to 
the β-lactamase genes (bla), which encode the enzymes NDM-1 (first NDM-variant 
observed) and CTX-M-15 (15th CTX-M-variant observed), respectively. Genes mentioned in 
this thesis are not included in the list above. 
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1 INTRODUCTION 
At the centre of attention of this thesis is the patient with bloodstream infection caused by 
extended-spectrum β-lactamase-producing Enterobacterales. Enterobacterales are Gram-
negative enteric bacilli of which the clinically most important species are Escherichia coli 
and Klebsiella pneumoniae.  E. coli is the most common cause of bloodstream infection 
(BSI). Extended-spectrum β-lactamase (ESBL) is an enzyme that causes resistance to 
cefotaxime, which is the first-line empirical treatment in Sweden for patients with suspected 
bloodstream infection. The rate of ESBL-production in E. coli increased rapidly in Sweden 
between 2000 and 2010 and meant that the first-line treatment more frequently was 
inadequate leading to treatment failure. Thus, it is important at an early stage to identify 
which patients have an infection with ESBL-producing Enterobacterales (EPE) to adjust the 
antibiotic treatment. This can be achieved either by prediction based on risk-factors (Study I) 
or by rapid diagnostic methods (Study II).  
Resistance genes are spread either through clonal expansion and transmission of nearly 
identical bacterial strains, or through horizontal transfer by plasmid-borne resistance genes 
between different bacteria. Appropriate measures for infection control depend on the route of 
transmission. Hence, it is important to study the molecular epidemiology of AMR bacteria to 
discern if a resistance gene is mainly clonal or mainly plasmid-borne (Study III). The 
severity of disease in patients with BSI caused by ESBL-producing E. coli is influenced by 
patient comorbidity and immune status. Whether also microbial factors have a significant 
impact on the severity of disease is unclear. Increased understanding of the pathogenesis of 
disease severity in EPE BSI could possibly identify properties that have a potential utility in 
future methods to identify patients with higher risk of severe infection or potentially become 
targets for new adjuvant anti-virulence treatment in sepsis (Study IV). 
1.1  ANTIMICROBIAL RESISTANCE IN E. COLI AND K. PNEUMONIAE  
1.1.1 Evolution of antimicrobial resistance 
The origin of most antibiotic resistance genes can be found in environmental bacteria, in 
many cases in antibiotic-producing Actinobacteria [1, 2]. The function of antibiotics in these 
bacteria was inter-cellular signalling and protection [3]. Resistance genes evolved in parallel, 
to protect the antibiotic-producing bacteria from the antibiotic action. There is evidence that 
resistance genes are ancient, vanA-genes have been found in Canadian High North 
permafrost-samples, dating 30,000 years ago [4]. In a previously completely closed cave in 
Lechuguilla Cave in New Mexico, which has been isolated from the surface eco-system since 
at least 4 million years, Paenibacillus species was found carrying antibiotic resistance genes 
to several antibiotics, including aminoglycosides [5]. The environmental resistome is a term 
that refers to all potential resistance genes, includes genes that confer phenotypic resistance, 
silent genes that are not expressed and pro-resistance genes which are genes that do not cause 
resistance in their present form, but in which only minor mutations are needed in order to 
cause resistance [2]. 
In the environmental resistome, genes are commonly located on the chromosome but 
sometimes on plasmids, which are mobile circular DNA-fragments (further described in 
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Section 1.5.2). The transfer from chromosome to plasmid is a relatively rare event, but when 
the resistance gene has been mobilied to a plasmid, it has a higher potential to spread to 
clinically relevant bacteria, termed pathogens. 
In the 1920s, before antibiotics were introduced to the clinic, common human pathogens were 
generally very susceptible to antibiotics. However, within a few years of the first introduction 
of each new class of antibiotics, pathogens with resistance to that class were observed 
(Figure 1) and rapidly spread [6].  
Figure 1. Timeline of antibiotic deployment and the evolution of antibiotic resistance. The year each 
antibiotic class was introduced in clinical use is shown above the timeline and the first observation of 
resistance below. Only a selection of antibiotic classes are shown [6]. Reprinted with permission. 
The global expansion of resistant bacteria that has occurred especially in the past 20 years is 
considered a serious threat to human health. It is caused by a complex relationship between 
antimicrobial use in humans and animals, antimicrobials from pharmaceutical industry, 
genetic events in microorganisms, the environment, international travel and transmission in 
hospitals and community (Figure 2) [7].  
The World Health Organization has identified pathogens of critical priority for development 
of new antibiotics [8]. The most critical pathogen is Mycobacterium tuberculosis, followed 
by carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas 
aeruginosa and third generation cephalosporin-resistant (3GCR, mainly due to ESBL) E. coli.  
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Figure 2. Ecology of antibiotics and antibiotic resistance. Selection and induction of antibiotic 
resistance occur in all ecological niches where antibiotics and bacteria co-exist. These include 
microbiota in humans, livestock/agriculture and the environment. Antibiotics in the environment come 
from human and hospital waste, food production and pharmaceutical industries. Resistant bacteria 
are circulated between the different niches [7]. Figure reprinted with permission. 
Cassini et al. have estimated the burden of disease of AMR bacteria in the European Union 
and the European Economic Area in 2015 [9]. The pathogen with the highest burden of 
disease was 3GCR E. coli for which the estimated number of infections were 297,416 and the 
number of attributable deaths 9,066. It seems like infections with AMR bacteria is added on 
the burden of infection of susceptible bacteria instead of replacing infections with susceptible 
strains. The burden is higher in southern European countries, especially Italy and Greece. 
Additionally, in these countries with high rates of antimicrobial resistance, there has been a 
shift in the species-distribution in bloodstream infections, with species such as Pseudomonas 
aeruginosa and Acinetobacter baumannii increasing. These species feature intrinsic 
resistance to many antibiotics, which further aggravates the burden of AMR [10]. 
1.1.2 Antibiotics with effect on Gram-negative bacteria 
The potential of an antibiotic agent to have effect on bacteria is heavily dependent on the 
bacterial cell wall. Gram-negative and Gram-positive bacteria have very different cell wall 
properties. Thus, the effect of an antibiotic agent is often limited to either Gram-positive or 
Gram-negative bacteria. Table 1 summarizes the target and major resistance mechanisms 
(explained in Figure 3) of clinically relevant antibiotics with effect on Gram-negative bacilli. 
The table also displays their activity on Enterobacterales producing the β-lactamases covered 
in this thesis: ESBL and New Delhi Metallo-β-lactamase (NDM).  
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Table 1. Overview of antibiotics with effect on Gram-negative bacteria in clinical use. Table 
originates from Morar et al. [3]. Modified and reprinted with permission.  
Antibiotic class Examples 
Activity  
against 
EPEA 
Activity  
against 
NDM 
-isolates [11] Target 
Mode of 
resistance 
β-lactams       
  Penicillins Ampicillin - - 
Cell membrane  
- peptidoglycan  
biosynthesis 
Hydrolysis 
Altered target  
Porin loss 
Efflux 
  3G-cephalosporins 
Cefotaxime (-) - 
Ceftriaxone (-) - 
Ceftazidime (-) - 
  Carbapenems 
Ertapenem + - 
Imipenem + +/- 
Meropenem + +/- 
  Monobactams Aztreonam - +/- 
  β-lactams with  
  β-lactamase- 
  inhibitors [12] 
Piperacillin-tazobactam + - 
Ceftazidime-avibactam + - 
Ceftolozane-tazobactam + - 
Meropenem-vaborbactam + +/- 
Other classes      
Aminoglycosides 
Amikacin 
Gentamicin 
Tobramycin 
+ 
+/- 
+/- 
(-) 
(-) 
(-) 
Translation 
Phosphorylation 
Acetylation 
Nucleotidylation 
Efflux 
Altered target 
Fluoroquinolones 
Ciprofloxacin 
Levofloxacin 
+/- 
+/- 
(-) 
(-) 
DNA replication 
Acetylation 
Efflux 
Altered target 
Pyrimidines/ 
Sulfonamides 
Trimethoprim/ 
Sulfamethoxazole 
+/- (-) 
Nucleotide synthesis 
- C1 metabolism 
Efflux 
Altered target 
Cationic peptides Colistin + + 
Cell membrane 
- lipid A 
Altered target 
Efflux 
Rifamycin Rifampicin (+) (+) Transcription 
Altered target 
Efflux 
Glycylcyclines 
(Tetracycline-
derivates) 
Tigecycline 
Eravacycline 
+ 
+ 
(-) 
(-) 
Translation 
Monooxygenation 
Efflux 
Altered target 
Phosphonic acid 
[13] 
Fosfomycin + (-) 
Cell membrane 
- peptidoglycan 
biosynthesis 
Decreased 
permeability 
Enzymatic 
modification 
ASusceptibility according to supplemental material for Study I. 
Legend for activity columns: + resistance uncommon (<20%); (+) agent should only be used in combination with 
other active agents; +/- resistance common (>20%); (-) usually resistant, susceptible isolates can occur; - always 
resistant. 3G: Third generation 
1.1.2.1 β-lactam antibiotics – structure and target.  
The β-lactam antibiotic group is the most widely used antibiotic class [12]. The main 
advantages with β-lactams are their low toxicity, high efficacy and that there is a variety of β-
lactams. Some have a narrow Gram-positive spectrum (e.g. phenoxymethylpenicillin) while 
other are broad-spectrum, potent antibiotics (e.g. meropenem). β-lactam-antibiotics are 
organic molecules with a β-lactam ring. They cause a bactericidal effect on dividing cells by 
their covalent binding that inhibits penicillin-binding-proteins (PBP). PBPs are important in 
stabilizing the cell wall when the cell wall is expanded after cell division. PBPs are 
transpeptidases that create peptide-cross-linking between the peptide chains when the 
peptidoglycan layer is built. There are many different PBPs. Each bacterial species has its 
own set of PBPs, often three to eight different types, of which usually one or two are 
essential. In Gram-negative bacteria PBP1a, PBP1b, PBP2 and PBP3 are essential [12]. 
Inhibition of PBP will arrest cell wall building and cause cell death. The different sub-classes 
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of β-lactam agents have different affinity to different PBPs, which explains the difference in 
antimicrobial spectrum. 
1.1.2.2 β -lactam-β-lactamase inhibitor combinations 
Combining a β-lactam with a β-lactamase-inhibitor restores the activity of the β-lactam. The 
β-lactamase-inhibitor acts as a suicide inhibitor as it is hydrolysed by the β-lactamase during 
the reaction that causes inactivation of the β-lactamase. Amoxicillin-clavulanic acid, 
piperacillin-tazobactam, ceftazidime-avibactam, ceftolozane-tazobactam and meropenem-
vaborbactam are combinations that have effect on ESBL-producing Enterobacterales (EPE) 
(Table 1 and Table 2) [14]. Avibactam and vaborbactam are more potent β-lactamase 
inhibitors than tazobactam and have effect both on EPE and some carbapenemase-producing 
isolates, but not on metallo-β-lactamases (e.g. NDM) [15].   
1.1.2.3 Cephalosporins 
As penicillins mostly have Gram-positive activity, the cephalosporins were developed for 
enhanced activity on Gram-negative bacteria. The first cephalosporins were oral, and 
resistance developed rapidly, with the TEM-1 penicillinase first observed in 1974. Since then, 
several generations of cephalosporins were developed [12]. The 1st generation cephalosporins 
are cefaclor and cefalexin. 
2nd generation cephalosporins include oral compounds such as cefadroxil, which is used for 
uncomplicated cystitis and as a screening substance for EPE in some countries. Cefuroxime, 
which has some effect on Gram-negative bacteria, but more pronounced Gram-positive 
activity also belongs to this group [12]. 
3rd generation cephalosporins (called extended-spectrum cephalosporins) including 
cefotaxime, ceftriaxone, ceftazidime and ceftibuten, were very potent when they were 
introduced in the clinic in the 1980s and quickly became first-line treatment for Gram-
negative infections [12]. Cefotaxime is still the empirical treatment of choice for suspected 
Gram-negative infection in immunocompetent patients in low resistance-prevalence countries 
such as Sweden. The increase in resistance to these antibiotics (3GCR), mainly caused by 
extended-spectrum β-lactamases, ESBLs, is a public health threat [8]. 
4th generation cephalosporins, e.g. cefepime, is not widely used in Sweden. The antimicrobial 
spectrum is similar to 3rd generation cephalosporins and ESBLA-production also causes 
resistance to cefepime. However, cefepime has higher hydrolytic stability to AmpC-enzymes 
compared with the 3rd generation cephalosporins [16].  
5th generation cephalosporins include ceftolozane which is combined with tazobactam. It has 
an improved effect on isolates with porin-loss and has a potent effect on Pseudomonas 
aeruginosa, but also on EPE [12, 14]. However, resistance may occur through 
hyperproduction of AmpC cephalosporinase, which can develop during therapy [17]. Other 
agents in this group are ceftaroline and ceftobiprole that have anti-MRSA effect in contrast to 
all other β-lactam-antibiotics, but the Gram-negative activity is similar to that of cefotaxime.      
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1.1.2.4 Carbapenems 
The carbapenems (ertapenem, imipenem, meropenem) have the broadest spectrum of β-
lactam antibiotics and they are stable against hydrolysis by ESBL- and AmpC-
cephalosporinases [12]. They are, however, susceptible to hydrolysis by carbapenemases. 
Some carbapenemase-producing isolates can retain a degree of susceptibility to meropenem 
and/or imipenem. These agents are thus still useful in combination therapy for 
carbapenemase-producing isolates.  However, NDM-producing isolates often have high-level 
resistance to meropenem, particularly this is true for K. pneumoniae [18].  
1.1.3 Resistance mechanisms 
1.1.3.1 Overview 
There are four principal bacterial resistance mechanisms that inactivate the effect of 
antibiotics (Figure 3) [19]: A) Impermeability. In Gram-negative bacteria this means a loss 
or conformational changes of porins in the cell membrane [20]. This restricts the amount of 
antibiotics that can enter the periplasmatic space, which in combination with a β-lactamase 
aggravates the level of resistance. However, impermeability is often associated with 
decreased fitness, since important nutrients cannot enter [21]. B) Efflux pumps in the cell 
membrane cause active transport of antibiotics out of the cell. C) Target modifications can 
occur through resistance mutations or through enzymatic modification of the target site. D) 
Drug inactivation. Enzymes, either in the cytoplasm or in the periplasmatic space inhibit the 
activity by binding or through enzymatic degradation.  
Figure 3. Principal resistance mechanisms in Gram-negative bacteria [19]. Drug inactivation (d) is 
the major resistance mechanism for β-lactam antibiotics in Gram-negative bacteria. β-lactamase 
enzymes hydrolyse β-lactam antibiotics in the periplasmatic space between the inner and outer 
membrane in the bacterial cell wall. Reprinted with permission. 
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For β-lactam agents the two most important resistance mechanisms are enzymatic 
inactivation by β-lactamases in the periplasmic space and target modifications of PBPs (often 
due to expression of an alternative PBP). Porin loss can aggravate the effect of β-lactamases 
and efflux pumps are common causes of carbapenem resistance in Pseudomonas aeruginosa. 
However, in Enterobacterales the most prevalent and damaging resistance mechanism is β-
lactamase-production. 
1.1.3.2 β-lactamases in Enterobacterales 
There were more than 2,800 unique β-lactamases described by 2018 [15]. Table 2 
summarizes various aspects of the most clinically important β-lactamases. β-lactamases are 
located in the periplasmic space in the cell wall, where they hydrolyse the β-lactam-ring and 
thus inactivate the agent. The various β-lactamases have different substrate specificity, which 
means that they can only hydrolyse certain kinds of β-lactam classes. Every time a new class 
of β-lactam (developed to overcome the resistance caused by current β-lactamases) has been 
clinically introduced, new β-lactamases have evolved that also hydrolyse that class. 
Table 2. Overview of β-lactamases.  
Swedish 
ESBL- 
Terminology 
   Resistance phenotype
A   
Common name 
Ambler  
class Examples 
Pc./ 
1GC 3GC 
Carba- 
penem 
Diagnostic 
inhibitor 
Clinical 
inhibitor 
- 
Penicillinase A 
Staphylococcal 
enzymes 
Pc. only   - CLA, TAZ, AVI, VAB 
Oxacillinase D OXA-1 Oxacillin   - AVI 
Broad-spectrum 
penicillinase 
A TEM-1B, SHV-1 B x   - CLA, TAZ, AVI, VAB 
ESBLA 
Extended-spectrum  
β-lactamase 
A CTX-M, TEM B, SHV B x x  CLA CLA, TAZ, AVI, VAB 
ESBLM 
Plasmid AmpC 
cephalosporinase 
C 
pAmpC 
CIT, CMY, DHA 
x x  Cloxacillin AVI, VAB 
- 
Chromosomal AmpC 
cephalosporinase 
C cAmpC  x x  Cloxacillin AVI, VAB 
ESBLCARBA 
Serine carbapenemase A KPC, IMI, SME x x x Boronic acid AVI, VAB 
Metallo-β-lactamase B NDM, IMP, VIM x x x EDTA - 
Carbapenem-hydrolysing 
class D enzyme 
(Oxacillinase-derived) 
D OXA-48 x  x - AVI 
A”x” means that the agent is a substrate for the enzyme. The level of resistance varies, some isolates appear susceptible despite 
presence of the enzyme. 
BThere are hundreds of different TEM- and SHV- enzymes. Some can hydrolyse 3GC (ESBLA) and some (e.g. TEM-1 and 
SHV-1) only hydrolyse 1GC and are not classified as ESBLs. 
1GC: 1st generation cephalosporin; 3GC: 3rd generation cephalosporin; Pc.: penicillin; CLA: clavulanic acid; TAZ: tazobactam; 
AVI: avibactam, VAB: vaborbactam 
Table based on information in several reviews [15, 22-26]. 
 
In this thesis, the two terns ESBL and 3rd generation cephalosporin-resistant (3GCR) are 
widely used. The definition of the term ESBL used is the Swedish reporting definition, which 
includes both ESBLA (classic Extended-spectrum β-lactamase, inhibited by clavulanic acid) 
and ESBLM (plasmid-mediated AmpC-cephalosporinase, inhibited by cloxacillin). From 
clinical and infection-control perspectives, the spectrum of resistance (implications for 
treatment) and the location of the β-lactamase on a plasmid (implications for transmission) 
are more important than the type of inhibition, which is the rationale for this classification 
[25].  The term 3GCR denotes all isolates resistant to 3rd generation cephalosporins. In 
addition to ESBLA and ESBLM, this term includes isolates with chromosomal AmpC and 
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isolates with other resistance mechanisms, such as hyperproduction of penicillinase in 
combination with impermeability. However, in E. coli and K. pneumoniae most 3GCR is due 
to ESBLA. 
ESBLCARBA is the Swedish term for carbapenemase. The type of carbapenemase produced 
influences the level of resistance to carbapenems, diagnostic sensitivity of screening- and 
confirmation-tests and predicts resistance to ceftazidime-avibactam [15].  
New Delhi metallo-β-lactamases (NDM) and other metallo-β-lactamases (MBL), generate 
high-level resistance to carbapenems. They are thus easy to detect with diagnostic tests and 
are always resistant to ceftazidime-avibactam and meropenem-vaborbactam [27]. 
The OXA-carbapenemases that occur in Enterobacterales are found in the OXA-48-group, 
while many other OXA-carbapenemases (OXA-23-group, OXA-51-group, OXA-58-group) 
are restricted to Acinetobacter species [28]. OXA-carbapenemases often have a weaker 
hydrolysing effect on carbapenems than the other carbapenemases. Because of this, they are 
more difficult to identify but are still important from an infection control perspective as minor 
mutations, changes in expression or porin loss can rapidly cause high-level resistance to 
carbapenems. OXA-carbapenemases do not hydrolyse cephalosporins. Many, but not all, 
isolates are nevertheless resistant to cephalosporins due to cephalosporinases. They are 
always resistant to piperacillin-tazobactam and most types confer resistance to temocillin 
[29]. However, temocillin-resistance is not specific for OXA-carbapenemases and as was 
noticed in Study II, not all OXA-carbapenemases display in vitro resistance to temocillin. 
Temocillin susceptibility seem to be especially common with OXA-244, one of the members 
of the OXA-48-group (unpublished data). Thus, detection of OXA-carbapenemases is a 
challenge for laboratories. OXA-carbapenemases are inhibited by avibactam.   
The serine carbapenemase K. pneumoniae carbapenemase (KPC) is globally the most 
common carbapenemase and is inhibited by avibactam, vaborbactam and boronic acid [15]. 
However, resistance for ceftazidime-avibactam is described and can develop during 
treatment. In some cases, the resistance is caused by increased expression of KPC combined 
with porin loss [30].  
1.1.4 Global epidemiology of ESBL- and carbapenemase-producing E. coli 
and K. pneumoniae  
In many countries in Asia, where resistance data are available, more than 50% of E. coli in 
bloodstream infections are 3GCR (Figure 4). In most parts of northwest Europe, Canada, the 
USA and Australia the rate is less than 25% [31]. A majority is caused by enzymes in the 
CTX-M group, especially CTX-M-15 which is carried by the successful clone ST131 (see 
Section 1.5.3). 
The most notable rates of carbapenemase-production in K. pneumoniae (Figure 5) are 
reported from India (59% reported resistance in 2017, mainly NDM), Greece (66% in 2017, 
mainly KPC), Italy (32% in 2017, mainly KPC), the Middle East (17-70% in 2016-2017, 
mainly OXA-48) and Latin America (8-20% in 2013-2017, mainly KPC) [31-34]. In most 
countries in northwest Europe, USA, Canada and Australia less than 5% of K. pneumoniae 
are CPE. For E. coli, no countries report more than 20% carbapenem-resistance [31].  
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Figure 4. Resistance of E. coli to 3rd generation cephalosporins 2014-2017. Data from several 
sources (including EARS-Net and GLASS 2017) compiled by Center for Disease Dynamics, 
Economics and Policy. https://resistancemap.cddep.org. Data show aggregated resistance rates for 
isolates from blood and cerebrospinal fluid. Due to differences in sample collection and testing 
methods, rates should be interpreted with caution. For some countries rates are based on less than 
100 isolates. Light grey countries lack data. Note that the colour-scale is different compared with 
Figure 5 [31].  
 
Figure 5. Resistance of K. pneumoniae to carbapenems 2014-2017. Data from several sources 
(including EARS-Net and GLASS 2017) compiled by Center for Disease Dynamics, Economics and 
Policy, https://resistancemap.cddep.org. Data show aggregated resistance rates for isolates from 
blood and cerebrospinal fluid. Due to differences in sample collection and testing methods, rates 
should be interpreted with caution. For some countries rates are based on less than 100 isolates. 
Light grey countries lack data. Note that the colour-scale is different compared with Figure 4 [31]. 
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Information about the situation in Africa is scarce due to lack of structured AMR surveillance 
and in many cases lack of access to microbiological diagnostics. 
1.1.4.1 Local epidemiology of ESBL-producing E. coli and K. pneumoniae in Stockholm  
The rate of 3GC-resistance in E. coli from blood cultures sampled at Karolinska University 
Hospital increased rapidly from 2005 to 2012 (Figure 6). Since then the rate has stabilized 
around 10%. For K. pneumoniae the rate of ESBL-production was 7.5% in total in four 
Stockholm hospitals (Karolinska Huddinge, Karolinska Solna, Södersjukhuset and Danderyd 
Hospital) in 2018. Carbapenem-resistance occurred in less than 1% of both E. coli and K. 
pneumoniae in 2018 [35]. 
Figure 6. Proportion of E. coli from blood cultures sampled at Karolinska University Hospital that 
were cefotaxime-resistant (R) or intermediate (I), per year. Reduced susceptibility to cefotaxime is in 
most cases caused by ESBL (ESBLA or ESBLM) and the proportion reflects the increase of ESBL-EC. 
Local data from Karolinska University Laboratory. 
1.2 BLOODSTREAM INFECTIONS, SEPSIS AND SEPTIC SHOCK 
For recognized pathogens, such as E. coli and K. pneumoniae, a bloodstream infection means 
that the patient has a positive blood culture with the pathogen and this term is used 
synonymously with bacteraemia [36]. For skin commensal species that often cause 
contamination of blood cultures the definition of bloodstream infection/bacteraemia is more 
complex: the patient needs to have two positive blood cultures with the same species and at 
least one of the following symptoms: fever, chills or hypotension. Bloodstream infections 
usually originate in a localized infection in some part of the body, for example urinary tract 
infection, pneumonia, skin and soft tissue infections or an abdominal infection. Serious 
infections can cause sepsis, depending on the patient’s immune response. The 
pathophysiology in sepsis is complex and obscure despite intense research on the subject. 
Previously sepsis was described mainly as an overactivation of the immune response: an 
excessive activation of the immune response led to hyperinflammation, increased vascular 
permeability, coagulation and organ failure. However, this model has been revised and sepsis 
is now expressed as a dysregulation of the immune response since both pro- and anti-
inflammatory systems are activated at the onset of sepsis which causes a functional inhibition 
of inflammatory cells [37]. In 2016 the “Sepsis Definitions Task Force” published new 
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guidelines on the definition of sepsis (Sepsis-3) [38].  The new definitions read: 
”Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host 
response to infection.”  
“Septic shock is a subset of sepsis in which underlying circulatory and cellular/metabolic 
abnormalities are profound enough to substantially increase mortality.” 
The Sepsis-3 clinical criteria for sepsis and septic shock emphasise that an infection is a 
prerequisite for sepsis and they are based on the Sequential (Sepsis-related) Organ Failure 
Assessment (SOFA) score [38]. The SOFA score grades the level of organ failure based on a 
set of laboratory variables and clinical interventions. The clinical criteria for sepsis are a 
suspected or documented infection and an acute increase of ≥2 points of the SOFA score. 
Clinical criteria for septic shock are sepsis, the need for vasopressor therapy and an increased 
lactate despite adequate fluid resuscitation [38]. 
A simplified summary of some of the observations that supports the theory of dysregulation 
follows. Serum-levels of both pro-inflammatory (IL-1, IL-6 and TNF-α) and anti-
inflammatory (IL-10 and IL-1a) are simultaneously increased and then slowly decrease [37]. 
Neutrophilic granulocytes, a type of leukocytes which are important in the early response to 
pathogens, are increased in numbers, but are often dysfunctional, do not react appropriately to 
stimuli and have decreased ability to phagocytose pathogens [39]. Both cytotoxic T-cells and 
T helper cells are affected by increased apoptosis and fatigue. However, regulatory T-cells 
are not affected by this, which leads to immunosuppression. In addition, metabolic, endocrine 
and neuronal signalling pathways are also affected. Combined, the dysregulated immune 
response leads to organ failure and death in septic shock. If the patient survives it is common 
with a continued immunosuppression and dysregulation of the immune response, which can 
lead to secondary infections and increased mortality in a longer perspective.  
Further complicating the understanding and the possibility to develop immunotherapies for 
sepsis is that there is a pronounced heterogenicity between patients in their host response. A 
recent study analysed genome-wide gene expression in blood leukocytes from patients with 
sepsis admitted to the ICU [40]. Four endotypes with different expression profiles were 
identified based on the transcription-profiles. These four profiles differed in mortality and the 
proportion of patients with septic shock. One group of patients had an endotype characterized 
by a marked under-expression of genes involved in innate and adaptive immune functions. 
This group was associated with the highest mortality.  
Sepsis is thus an immunologically complex condition characterized by a dysregulated 
immune response, which in some individuals may lead to death. The level of dysregulation 
and immune expression varies between patients which probably means that individualized 
treatment and related diagnostic tests are necessary for success in the development of future 
immune-modulatory treatments for sepsis. Nevertheless, survival of bloodstream infections is 
not solely dependent on the host immune response – appropriate antimicrobial treatment and 
the virulence of the infecting microbe also play important parts. 
 
 12 
1.3 THE IMPORTANCE OF APPROPRIATE EMPIRICAL THERAPY 
In severe infections the time to appropriate therapy is vital for the survival of the patient [41, 
42]. In the absence of ultra-rapid, point-of-care diagnostic tests for detection of sepsis 
pathogens and resistance markers, to aid in the decision of antimicrobial treatment, empirical 
treatment needs to be initiated before the identity of the species causing the infection is 
known. The decision is based on the patient’s presentation, history and severity of illness. 
Invasive infections caused by ESBL-producing Enterobacterales (EPE) are associated with a 
high risk of receiving inadequate empiric treatment, and these patients seem to be at risk of 
higher mortality [43].  
In a study by Tumbarello et al., on 186 patients with bloodstream infection (BSI) caused by 
EPE, 48% of the patients received inadequate therapy. Out of these 60% died within 3 weeks, 
as compared with 18% of patients with adequate initial therapy [43]. However, in a Dutch 
study, inappropriate therapy within 24 hours was not associated with a higher mortality 
within 30 days in the multivariable analysis [44]. Other studies have also shown somewhat 
conflicting results on mortality and according to a review by Trecarichi et al., this is mostly 
due to limitations in sample sizes [45]. In this review, the authors report four studies with 
sample sizes larger than 342 patients. In three of these studies ESBL-production was 
independently associated with mortality. Although it has been difficult in some retrospective 
studies to show the impact of inappropriate therapy in ESBL-bacteraemia on mortality, a 
meta-analysis by Schwaber and Carmeli demonstrated a significant increase in mortality 
associated with ESBL-production [46, 47]. There is also no doubt that inappropriate therapy 
caused by resistant bacteria increases the length of hospital care and costs [46, 48]. 
Empiric treatment is given to treat the infecting organism, and when the organism is resistant, 
a favourable outcome is probably mostly due to the patients’ immune system and supportive 
therapy. Alternatively, the infection might be primarily a urinary tract infection with 
secondary bacteraemia, and that the high antibiotic concentration in the urine is sufficient 
despite resistance in vitro. The differences between mortality outcomes in different studies 
might be due to a difference in the severity of the infections included. In severe infections it is 
important that all treatment is optimized. ESBL-production by the infecting bacterial strain in 
sepsis was in one study identified as the most important predictor for readmission within 30 
days, with an odds ratio (OR) of 4.5 (p=0.01) [49].   
1.3.1 Risk factors for invasive infections with ESBL-producing 
Enterobacterales 
It is clear that it is important to identify patients with an increased risk of having an infection 
with an ESBL-producing strain when empirical treatment is initiated, especially in severe 
infections. Several studies have been performed to address the risk factors of ESBL 
bloodstream infection, including one Swedish study [50]. Trecharichi et al. reviewed 30 of 
these studies in 2012 [45]. The following risk factors were in several of these studies 
associated with ESBL BSI in multivariable analysis: Previous antibiotic treatment, especially 
third generation cephalosporins and fluoroquinolones; previous hospitalization, residency in 
long-term care facility and healthcare contacts; presence of indwelling devices, especially 
urinary tract catheterization; and presence of co-morbidities. Contrarily, in the Swedish study 
by van Aken et al. in 2014, a prior culture positive of ESBL-producing bacteria was the only 
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significant risk factor for BSI with ESBL in the multivariable analysis [50]. “A prior culture” 
probably included both screening and clinical cultures, but this is not clearly stated. However, 
the sample size in this study was quite small; only 70 cases of BSI caused by ESBL-
producing E. coli and 140 non-ESBL E. coli controls were included.  
One problem with many of the previous studies is that they include both community- and 
hospital-acquired infections, without separate analysis. This is unfortunate, since these two 
patient groups are very different. Rodriguez-Bano et al. studied risk factors for ESBL E. coli 
BSI in two separate studies, one on community-acquired BSI and one on nosocomial BSI 
[51, 52]. They compared the same cases (ESBL-EC BSI) with two separate control groups: 
non-ESBL E. coli BSI and all patients with suspected BSI. They found that somewhat 
different risk factors were associated with ESBL E. coli BSI in nosocomial BSI and 
community-onset BSI. In the study on nosocomial BSI, the risk factor with the strongest 
association to ESBL-producing E. coli was previous use of third generation cephalosporins 
[51]. This variable had a significant association regarding both control groups used, patients 
with nosocomial BSI, and patients with nosocomial BSI caused by non-ESBL E. coli. The 
association was stronger when compared with non-ESBL E. coli than when compared to 
suspected BSI-controls, which supports the theory described above that the importance of 
previous antibiotic treatment is exaggerated when compared with susceptible strain 
infections. In the second study, on community-onset BSI, three variables were associated 
with ESBL-EC in multivariable analysis when compared to both control groups: healthcare 
associated bacteraemia, urinary catheter use and recent antimicrobial use [52]. 
At least five additional studies on risk factors for ESBL-production in community-onset BSI 
have been published in recent years, from Israel, South Korea and China [53-57]. The design 
of the studies varies, which makes them difficult to compare, and in several of them 
susceptible strains of the same species have been used as controls. However, the variables 
that were associated with ESBL in more than two of these studies in multivariable analysis 
were: 1) admission from long-term care facility/healthcare-associated infection, (four studies) 
[53-56]; 2) recent use of antibiotics/previous third generation cephalosporin use/admitted on 
antibiotics (four studies) [54-57]; and 3) severe infection at admittance (two studies) [54, 56].  
1.3.2 The importance of local epidemiology 
The risk factors for infections with ESBL-producing bacteria vary between different regions 
and are related to the level of resistance. For example, in the Chinese study of risk factors of 
ESBL BSI by Quan et al., 55% of E. coli recovered from blood cultures were ESBL-positive, 
[55] while the resistance level was still below 10% in Sweden in 2014 [58]. Therefore, it is 
not possible to apply a risk-scoring system developed in another epidemiological setting, 
without local validation and adaptation.  However, due to differences in sampling practices, it 
is difficult to compare resistance rates from different regions. For example, in some countries 
blood samples are only taken in treatment failures or nosocomial infections, which of course 
results in a higher proportion of resistant isolates.  
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1.3.3 Predicting the probability of infection with ESBL-producing 
Enterobacterales at admission to hospital 
One of the most important reasons for studying risk factors for BSI with ESBL-producing 
bacteria, is the desire to be able to identify patients at risk for having this type of infection, at 
the time empiric therapy is initiated. However, the source population in many of the studies 
described above does not adequately reflect the patient population in which the question of 
suitable empirical therapy arises, which is further discussed in the methods section (Section 
3.1.1.1). Additionally, the odds ratios for several of the associated variables are usually quite 
small, although significant, and the predictive value is thus limited.  
As Rottier et al. showed in a Dutch study 2015, basing therapy decisions solely on previous 
carriage with ESBL-producing Enterobacterales (EPE) or antibiotic treatment leads to 
unnecessary use of broad-spectrum antibiotics [59]. They evaluated the effects of Dutch 
recommendations to give broad-spectrum antibiotics (third generation cephalosporin + 
aminoglycoside, or carbapenem) to all patients with suspected sepsis of unknown origin who 
had previously documented EPE-colonization or previous cephalosporin/fluoroquinolone use. 
In this study, the positive predictive value (PPV) of prior colonization of with ESBL <3 
months was 7.4, while the PPV was only 1.8, when both prior EPE-colonization <3 months 
and use of cephalosporin/fluoroquinolones <1 month were considered. The authors concluded 
that strict adherence to the guidelines would, for bacteraemia caused by Enterobacterales, 
lead to an overtreatment rate of 14%, a rate of carbapenem use of 18% and an inappropriate 
treatment rate of 3.5%. The corresponding rates for following guidelines, but disregarding 
previous antibiotic use, were a carbapenem use rate of 7.4%, an overtreatment rate of 4% and 
an inappropriate treatment rate of 4.2%. Thus, decreasing the inappropriate treatment to a 
minimal extent from 4.2% to 3.5%, would lead to a considerable amount of overtreatment 
with carbapenems.  
In Italy, Tumbarello et al. developed a risk-scoring system in order to identify patients having 
infections with ESBL-producing bacteria, at admission to hospital [60].  The cohort consisted 
of patients admitted to hospital and the controls were matched for hospital ward and month of 
admission. In the risk-scoring system, they included the following variables that were 
associated with isolation of ESBL-producing Enterobacterales from a clinical sample: recent 
hospitalization, admission from another healthcare facility, Charlson co-morbidity index ≥4, 
previous therapy with β-lactams or fluoroquinolones, history of urinary catheterization, and 
age ≥70 years old. The different variables were assigned a score of 2 or 3. A total score of ≥6 
gave a PPV of 82% and NPV of 81% for any infection (i.e. growth in clinical sample) caused 
by ESBL-producing bacteria. In their derivation cohort, only 17% were from blood samples, 
the other samples were from urinary tract (64%), skin and soft tissues (12%), lower 
respiratory tract (7%), biliary tract (4%), and surgical wounds (2%). However, patients with a 
known history of infection with ESBL-producing bacteria were excluded in this study. The 
Tumbarello-model thus predicts the probability of having any infection with ESBL-producing 
bacteria in patients without known history of ESBL-infection and admitted to hospital, 
regardless of clinical diagnosis. 
The Tumbarello-model has been validated and adapted to local conditions in North Carolina, 
USA, by Johnson et al. [61]. In this study the cohort also consisted of patients admitted to 
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hospital, and cases were patients with any clinical sample positive for ESBL-producing 
bacteria. However, it is unclear whether patients with previous history of infection with 
ESBL-producing bacteria have been excluded, as they were in the Italian study. The 
distribution of sample sources was similar to that of the Italian study, as 15% were derived 
from blood cultures. The authors adapted the Italian model, by exchanging some variables, 
and changing the score of others. In this model, called the Duke model, the following 
variables were included: previous hospitalization; transfer from another healthcare facility; 
previous therapy with β-lactams or fluoroquinolones; recent history of urinary 
catheterization; and immunosuppression. With the Duke model, a score of ≥8 gives a PPV of 
79% and an NPV 85% for having any infection with ESBL-producing bacteria. Given this, 
and if patients with a score of ≥8 were given empiric therapy covering ESBL-producing 
bacteria, 85% would have been given appropriate therapy, 3% overtreatment, and 12% 
inappropriate treatment. 
In another study in the Netherlands, Plattel et al. tried to establish a system for predicting 
ESBL-carriage (not infection) at admittance to hospital, but failed with this objective since 
they could not find any sufficiently discriminatory variables [62].  
1.4 METHODS FOR SUSCEPTIBILITY TESTING OF BACTERIA 
1.4.1 MIC-determination  
The reference method for AST according to ISO20776-1 is Minimal Inhibitory Concentration 
(MIC)-determination by broth dilution [63]. A standardized inoculum is added to tubes or 
microtiter-wells with antibiotics in specific concentrations with doubling dilution steps 
including the concentration 1 mg/L and incubated 16-24 hours depending on species. The 
MIC is the lowest concentration that prevents visible growth after this time.  
Figure 7. Broth microdilution with a Sensititre panel read with Vizion software (Thermo Fisher 
Scientific, Waltham, Massachusetts). ESBLA-producing E. coli from an external quality control 
programme. Photo from Karolinska University Laboratory. 
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Traditionally this has been a labour-intensive method, and it has not been available in most 
laboratories. A commercially available product for broth microdilution (BMD) susceptibility 
testing is Sensititre® (Thermo Fisher Scientific, Waltham, Massachusetts), which offers 
standard panels with pre-prepared antibiotic dilutions in 96-well microtiter plates (Figure 7) 
[64]. The most common method for routine MIC-determination in clinical laboratories is 
MIC-determination with gradient tests. Plastic or paper strips with a predefined gradient of 
antibiotic concentrations are placed on Mueller-Hinton agar inoculated with a bacterial 
suspension [65]. However, this method is unsuitable for certain antibiotics, such as colistin 
[66] and EUCAST has since 2015 issued several warnings concerning the performance of 
gradient tests for some antibiotics, including piperacillin-tazobactam [67].  
1.4.2 Disk diffusion 
Prediction models for identifying patients at risk for bloodstream infection caused by ESBL-
producing bacteria at admittance could be an important aid in improving empirical therapy. 
However, definite therapy must always be guided by identification of the causing species and 
susceptibility testing. In most cases this is done by bacterial culture in blood culture systems, 
followed by species identification with matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) or phenotypic tests. Time to detection in blood 
culture systems is usually 4-48 hours (for Enterobacterales mostly less than 24 hours) with 
species identification possible within 1- 4 hours after the blood culture bottle has turned 
positive.  
Culture is followed by susceptibility testing, which traditionally unfortunately requires 
overnight incubation, further delaying susceptibility results with at least 16 hours. The routine 
susceptibility testing method recommended by the European committee of antibiotic 
susceptibility testing (EUCAST), is EUCAST disk diffusion ( 
Figure 8) [68]. Bacterial colonies are suspended in saline solution to a density of 0.5 
McFarland. The suspension is inoculated on Mueller-Hinton agar plates (or Mueller-Hinton 
Fastidious agar), and standardized antibiotic disks are applied on the inoculated plates. After 
16-20 hours of incubation, the inhibition zones are measured with a pair of callipers. The 
inhibition zones measured are interpreted as “Susceptible, “Susceptible, Increased exposure” , 
or “Resistant” according to breakpoints provided in EUCAST breakpoint tables [68].  
Disk diffusion is an old and manual method, which requires trained staff and quality control 
for accurate results but has several advantages over new automated methods [69]. Apart from 
staff costs, the method is cheap, well validated and flexible. The selection of antibiotics that 
are tested can easily be adapted for local needs, sample types, resistance patterns and new 
antibiotic agents. The latter is an important point, in the development of new antibiotic 
agents, the most suitable disk strength for disk diffusion is developed in parallel with clinical 
trials. This means that disk diffusion disks are often commercially available within a few 
months of the approval of a new antibiotic, while the process of validating and developing 
automated AST methods often take more than two years [69].  
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Figure 8. EUCAST disk diffusion photographed at 18 hours of incubation. NDM-producing  
K. pneumoniae from Study II. The isolate was resistant to all tested antibiotics including piperacillin-
tazobactam, cephalosporins, carbapenems, aminoglycosides, fluoroquinolones, and trimethoprim-
sulfamethoxazole. Photo taken at Karolinska University Laboratory with BD Kiestra TLA. 
 
1.4.2.1 Automation of disk diffusion 
Although disk diffusion traditionally is manual, there is a huge potential for full automation, 
including streaking of plates, application of antibiotic disks, incubation, photography and 
reading of inhibition zones, and some studies have shown improved standardization of disk 
diffusion with automation [70, 71]. Some fully automated methods for disk diffusion exist, 
such as WASPTM system (Copan Italia SpA, Brescia, Italy) [71] and there are also specialized 
instruments for automatic reading of inhibition zones such as SIRscan (i2a diagnostics, 
Montepellier, France) [70], Scan 4000 (Interscience,  Saint Nom, France) [72] and the stand-
alone software AntibiogramJ [73]. For the total lab automation systems such as the BD 
KiestraTM TLA/WCA [74, 75] in use at Karolinska University Hospital, the important steps in 
disk diffusion – spreading of plates, application of disks and assigning inhibition zones on 
digital images – are nevertheless still manually performed by laboratory technicians. A 
limitation for automation is that specialized software for reading of inhibition zones in many 
cases is restricted to the software supplied by the automation company, and a competing 
software that might be better for disk diffusion reading is difficult (almost impossible) to 
implement. A total lab automation system is an expensive investment for a laboratory and is 
not easily changed. This means that the laboratory is dependent on the willingness of the 
company to develop and validate automated reading of disk diffusion. 
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1.4.3 Phenotypic versus genotypic methods 
As was described in Section 1.1.3 bacteria can have many different resistance mechanisms 
that can co-act and together confer a higher level of resistance. For some resistance 
mechanisms, e.g. porin loss, there are many different genes. Additionally, changes in the 
regulation of expression can influence the level of resistance [76]. 
Phenotypic methods such as BMD and disk diffusion described above can be used both for 
demonstrating susceptibility and resistance. However, while PCR-based methods are rapid, 
they can only demonstrate the presence of a resistance gene [77]. For some genes, such as 
NDM, this reliably predicts phenotypic resistance for β-lactam-antibiotics. But other genes 
might be present without causing a clinically relevant resistance. With advances in whole 
genome sequencing techniques, this method could potentially be developed for prediction of 
resistance and possibly susceptibility but it will require advanced bioinformatic power and 
continuous development and validation against phenotypic methods to ensure detection of 
previously unknown resistance mechanisms not included in the database [76].  
1.4.4 Rapid methods for susceptibility testing 
Species identification is necessary for susceptibility interpretation. While the development of 
MALDI-TOF MS has revolutionized laboratory work in clinical microbiology, by shortening 
the time for isolate species identification from 20 hours to 15 minutes, a comparably rapid 
and reliable method of susceptible testing is still lacking [77]. 
As discussed above, PCR-based approaches are only able to identify resistance, but not 
susceptibility. Several PCR-based rapid methods for detection of sepsis pathogens, e.g. 
FilmArray® (BioFire, Salt Lake City, Utah) include selected resistance genes, for example 
KPC, which can be useful in high-prevalence regions [78, 79].  
Currently there are many efforts to find ways to shorten the time for AST, including among 
others, digital time-lapse cytometry, microfluidic platforms, automated digital microscopy, 
two-photon excitation fluorometry, and mass-spectrometry based approaches [65, 77, 80-86]. 
Some of the new methods show promising results, but they are still labour-intensive, 
expensive and commonly suitable only for single sample tests and a limited number of 
antimicrobials. In relation to other methods, rapid disk diffusion has a potential as a cost-
effective and flexible method if reproducible and accurate results can be produced. At the 
time of publication of Study II, there were some conference abstracts but only a few 
published studies describing the potential of rapid disk diffusion [87-90].  
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1.5 MOLECULAR EPIDEMIOLOGY AND VIRULENCE 
The study of molecular epidemiology and genetic characteristics of bacterial strains is 
important for understanding of the transmission and evolution of resistance and virulence of 
bacteria. A correct understanding of transmission and selection mechanisms are vital for 
development of appropriate intervention strategies to limit antimicrobial resistance and to be 
able to identify transmission events and outbreaks in clinical settings. Identification of 
important virulence factors for infection and severity can also suggest potential targets for 
future treatment [6]. The methods referred to in this chapter are described in detail in the 
methods Section 3.3. 
1.5.1 Evolutionary phylogeny of E. coli  
The evolution of E. coli has been studied in detail because E. coli is such a diverse species, 
with individuals ranging from harmless commensals to highly pathogenic 
Enterohaemorrhagic E. coli (EHEC), Enteropathogenic E. coli (EPEC), Enteroinvasive E. 
coli (EIEC) and Shigella species. Molecular studies have shown that Shigella is so closely 
related to E. coli that they are phylogenetically the same species, but Shigella carries 
important toxins causing a clinically well-recognized presentation which motivates keeping 
the name and distinction of Shigella [91].  
The classic division of E. coli into phylogroups, A, B1, B2, D was proposed by Ochman and 
Selander in 1984 based on results of multilocus enzyme electrophoresis (MLEE) and further 
developed by Clermont et al. in 2013 with addition of the phylogroups C, E and F based on 
multilocus sequence typing (MLST) [91, 92]. As Wirth et al. showed in 2006, the original 
phylogroups were relevant from an evolutionary perspective, but more detailed insights in the 
phylogenetic relationship within E. coli could be elucidated with Achtman’s MLST [91]. 
Although there was a good concordance between STs and phylogroups, there were also some 
intermediate groups with a mixture of genetic material from different phylogroups, as 
evidence of recombination. These intermediate groups were named ABD and AxB1. Their 
analysis indicated that the current E. coli population probably evolved from a common 
ancestor some 10-30 million years ago, after a bottleneck decrease in the population had 
occurred. The four ancestral phylogroups had then evolved clonally, but with different 
degrees of recombination. The amount of recombination is of importance for the study of 
phylogeny, since the horizontal gene transfers confuse the building and interpretation of 
phylogenetic trees. The extent to which recombination has occurred during evolution and 
continuously occurs, differed between the various phylogroups. According to the MLST-
based analysis of Wirth et al., the most conserved phylogroup was B2, while ABD was the 
most recombinant. Shigella and EIEC mostly belonged to ABD and B1. Other pathogenic E. 
coli were also associated with a high level of recombination (EIEC belonged to ABD, B1 and 
AxB1, EPEC to ABD, B1 and B2). The authors suggested that the high recombination in 
these pathogens possibly could be caused by a reduced function of the methyl-directed 
mismatch repair (MMR). A deficiency in this post-replicative repair system causes both a 
high mutation rate and high transfer rate. This gave these strains an advantage to enter and 
stay in the pathogenic niche, instead of in the commensal niche, since they need to adapt to 
the continuous selective pressure of the human immune system [91].  
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Interestingly however, ST131 (see detailed description below), which was responsible for a 
substantial part of the expansion of ESBL-producing E. coli belonged to phylogroup B2 and 
had a low rate of recombination in the core genome [93]. For ESBL-producing E. coli in 
Sweden, there was also a difference between the phylogroups found in the commensal faecal 
microbiota of carriers and those found in bloodstream infections [94]. In both groups 
phylogroup D was common. Phylogroups A and B1 were associated with faecal carriers, 
while phylogroup B2 (mainly ST131) was associated with bloodstream infection. This 
indicates that not only the level of recombination is important for pathogenicity and clonal 
expansion, other variables are also important. 
1.5.2 Definition of high-risk clones and successful plasmids 
The global increase of AMR in Enterobacterales is mainly driven by two mechanisms: 
successful high-risk clones and horizontal plasmid transfer [95]. Successful high-risk clones 
have been shown to have an epidemic potential and are common in all parts of the world. A 
clone in microbiology refers to closely related strains with a common ancestor. However, all 
individuals in a clone do not have identical genomes, small differences will always exist 
caused by mutations, horizontal gene transfers and recombination events [96]. Multidrug 
resistant (MDR) high-risk clones have been defined as clones that 1) show international 
distribution; 2) possess several types of clinically important resistance traits (MDR) 3) are 
able to colonize hosts for a prolonged period of time; 4) are efficiently transmitted between 
hosts; 5) show extended pathogenicity and fitness; and 6) are able to cause severe and/or 
recurrent infections [95-97]. The spread of these high-risk clones is due to a combination of 
acquired genetic properties enhancing the abilities described and the selective pressure of 
antimicrobial treatment [95].  
Horizontal transfer of genes and plasmids is the second mechanism. According to Baquero 
and Coque, the potential success of these mobile genetic elements depends on four different 
properties necessary for transfer of a plasmid or transposon from one individual to another: 
“penetration (ability to reproduce and spread), promiscuity (ability to exchange information), 
plasticity (variability) and persistence (construction of durable links with its environment).”  
[98]. One important property is the promiscuity, i.e. if the plasmid can only transfer between 
closely related individuals (within the same group or species or even clone) or if inter-species 
transfer is easy. Plasmids are divided into groups by the incompatibility group typing (Inc). 
The DNA-region in the plasmid that the Inc-grouping is based on, is a region that is necessary 
for replication of DNA. This is a conserved region, in contrast to other coding regions of the 
plasmid, which often undergo mutational and horizontal gene transfer changes [96]. IncF is 
an example of a narrow-host range plasmid, while IncA/C, IncL/M and IncN belong to the 
broad-host range group and can easily be transferred between species [96, 99]. This property 
of horizontal transfer is important. Since the plasmid may transfer to many different 
individuals (belonging to the same or a different species) that are found in close vicinity of 
each other in the microbiota, it is thus not dependent on the fitness of the original clone. 
Plasmids can thereby sometimes have a greater importance for spread of resistance genes 
than high-risk clones. One example is the rapid spread of the colistin-resistance gene mcr-1, 
which has disseminated around the world and can be found in many different clonal groups 
and species, carried by plasmids such as IncI2 and IncX4, among others [100]. 
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Although IncF plasmids are narrow-range plasmids, they are still very important, since they 
are the type that carries blaCTX-M-15 in E. coli ST131. Other high-risk clones also often carry 
important AMR genes on IncF plasmids, which are called epidemic plasmids [96]. One 
reason for the success of these plasmids is that they are stable and are reliably reproduced in 
both bacterial daughter cells after a cell division. 
It is important to have a correct understanding of transmission and spread of AMR bacteria to 
develop appropriate strategies for intervention of transmission. For this reason, studies like 
Study III are important to clarify the role of high-risk clones relative to plasmid transfer. 
1.5.3 E. coli ST131 – a high-risk clone 
As described above, E. coli is an extremely diverse species, both in virulence and resistance, 
with members of the species ranging from harmless gut colonizers, to potentially lethal toxin-
producing Enterohaemorrhagic E. coli. Since the genes encoding ESBL-enzymes are carried 
on plasmids, ESBL-enzymes can be present in basically any strain-type. However, there is 
one highly successful clone called ST131, which is responsible for a substantial part of the 
increase of ESBL-producing bacteria around the world [101, 102]. Although ST131 is the 
dominant clone, there are also many other E. coli lineages which are associated with ESBL-
production, for example ST405, ST59, ST10 and ST23 [103]. 
ST131 is divided into the clades A, B and C. ST131 clade C consists of two subclades, ST131 
C1 and ST131 C2. The previous nomenclature “ST131 H30-R” refers to clade C and “ST131 
H30-Rx” to clade C2. ST131 clade C is characterized by resistance to fluoroquinolones (FQ) 
due to mutations in gyrA and parC [104-106]. Ben Zakour et al. studied the evolution of 
ST131 and concluded that clade C separated from Clade B in the middle of the 1980s. Clade 
C is characterized by its acquisition of the mentioned FQ-mutations, which occurred at the 
same time as the clinical introduction of fluoroquinolones. Shortly thereafter clade C2 
diverged, concomitant with the acquisition of blaCTX-M-15, which is almost uniformly found in 
this subclade. ST131 C2 expanded exponentially during the 1990s and 2000s and is today the 
dominating subclade. ST131 C1 has also acquired CTX-M, but several different types, both 
blaCTX-M-14 and blaCTX-M-27 are common [107]. The evolution of ST131 in Sweden followed 
the same pattern as the international expansion and the current population was shaped by 
several introductions of ST131 into Sweden in combination with national transmission events 
[108]. 
ST131 is not only associated with multidrug-resistance, it has also a high number of virulence 
genes. With a few exceptions, nearly all ST131 are classified as extra-intestinal pathogenic E. 
coli (ExPEC, see below). ST131 is the dominating clone in bloodstream infections, with 
reported proportions of 20-60% of ESBL-producing E. coli from these infections [101, 109].   
As discussed above, recombination seems to be important and frequent in pathogenic E. coli 
but ST131 is an exception. McNally et al. showed that the expansion of ST131 coincided 
with a marked reduction in recombination. One explanation could be that after ST131 had 
acquired genes associated with virulence and resistance genes, another genetic event 
decreased the recombination and mutation frequency, leading to a clonal expansion [93]. 
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1.5.4 K. pneumoniae ST258 – a high-risk clone 
The most successful K. pneumoniae clone is the KPC-producing ST258 and closely related 
ST512. These clones have greatly contributed to the spread of carbapenem-resistant K. 
pneumoniae, from its probable origin in USA where it was first described in 1996, to  a large 
part of the world [103, 110]. KPC is endemic and the predominant carbapenemase-type in 
North America, South America, Greece, Italy, Israel and China [34, 111]. The clonal 
expansion is to a great extent caused by nosocomial transmission routes [33]. The blaKPC 
gene has also been reported in isolates belonging to many other sequence types and clonal 
complexes [103].  
1.5.5 ExPEC virulence factors 
E. coli isolated from extra-intestinal infections such as UTI, abdominal infections, pneumonia 
and meningitis, are termed Extra-intestinal pathogenic E. coli (ExPEC) in order to distinguish 
them from the other intestinal pathogenic E. coli such as EIEC, EHEC and EPEC. In 
discussion of virulence traits, ExPEC is an umbrella term that comprises several subtypes 
called urinary pathogenic E. coli (UPEC), neonatal meningitis pathogenic E. coli (NMEC) 
and avian pathogenic E. coli (APEC) [112, 113]. The definition of ExPEC is not 
straightforward, a common definition is that the isolate is recovered from an extra-intestinal 
infection. There have been several attempts to molecularly define ExPEC and UPEC 
respectively. ExPEC has been defined as presence of two or more of the following virulence 
genes: pap, sfa/foc, afa/dra, kpsMT and iutA [114]. The definition of UPEC is presence of 
three or more of the genes chuA, fyuA, vat and yfcV [115]. However, these definitions do not 
encompass all the variation in isolates causing extraintestinal infections. Other genes are also 
associated with ExPEC virulence. The most important are presented in Figure 9 and Table 3 
and the functions of the main types of virulence factors are briefly described below [116, 
117]. Most of these genes have been identified in studies comparing isolates from clinical 
infections with faecal or environmental samples.  
1.5.5.1 Adhesins 
The function of adhesins is to facilitate adherence to structures in the urinary tract. Most 
ExPEC infections with E. coli are derived from the faecal microbiota, so the ability to attach 
to the urinary epithelium is essential for the development of UTI [116, 117].  Fimbrial 
adhesins, or pili, are anchored in the bacterial cell wall and adheres to their receptors through 
tip-located adhesins. For Type 1 Fimbriae this tip consists of FimH, which is almost always 
present in E. coli and has been used for subtyping of strains. The classification of ST131 H30 
(i.e. fimH allele 30) mentioned in Section 1.5.3 is based on typing of the fimH-gene. Pap-
fimbriae are associated with pyelonephritis.  
1.5.5.2 Immune evasion 
Bacterial infection induces a strong host immune response. Bacteria in the blood are normally 
rapidly killed by the complement system or are opsonized and subsequently killed by 
phagocytes. However, ExPEC isolates have several mechanisms to protect the bacteria from 
this. Two factors that are associated with serum resistance are capsular polysaccharides, 
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especially belonging to group 2 capsular antigens (kpsMT) and a cell membrane-bound 
lipoprotein encoded by a gene called iss, increased serum survival [112, 117]. 
1.5.5.3 Invasion 
Invasion virulence factors are especially associated with the NMEC subtype of ExPEC, 
where e.g. ibeA, ompA and fdeC increase the ability of the bacteria to invade through the 
blood-brain barrier and cause cellular invasion in other infection types [118]. 
1.5.5.4 Iron uptake-siderophores 
Iron is an essential nutrient for bacteria, but in the urinary tract there is a limited amount of 
iron. Hence, bacteria with increased ability to absorb low amounts of iron have an infectious 
advantage [116]. 
1.5.5.5 Toxins 
Toxins are secreted into extracellular space where the toxins damage host cells, which 
contributes to symptoms in infection. The lysis of host cells causes release of nutrients 
(including iron) that the infecting bacteria can utilize [116]. 
 
Figure 9. Schematic figure of principal ExPEC virulence factors [116]. Reprinted with permission. 
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Table 3. Overview of important virulence traits with published association with ExPEC. 
Group Operon Name 
Included in 
definition of 
ExPEC/ 
UPEC Reference* 
Included in  
Study IV 
Adhesins 
afa/dra Dr Adhesins fimbriae ExPEC A Yes 
Sfa/foc F1C fimbriae/S-fimbriae ExPEC A Yes 
pap P-fimbriae ExPEC A Yes 
fim Type 1 fimbriae  A Yes 
bma M fimbriae  B No 
clpG Fimbrial adhesin CS31A  B No 
F17 F17 fimbriae  B No 
iha Adhesin-siderophore  B No 
Immune 
evasion 
K1 K1 Capsular antigen (subset of group 2)  B No 
K2 K2 Capsular antigen (subset of group 2)  B No 
kfiC K5 Capsular antigen (subset of group 2) ExPEC C Yes 
kpsMT Group 2/3 capsule ExPEC A Yes 
iss Increased serum survival  C Yes 
tcpC Tir domain containing protein tcpC  A Yes 
traT Serum-resistance associate protein  B No 
Invasion 
aslA 
Putative arylsulfatase ser-type periplasmic 
non-aryl sulfatase 
 A Yes 
fdeC Invasin, adhesin FdeC  A Yes 
ibeA 
Invasion protein IbeA pyridine nuclotide-
disulfide oxidoreductase 
 A Yes 
aap Anti-aggregation protein dispersin  B No 
ompA Outer membrane protein A  A Yes 
ompT Outer membrane protease VII  D Yes 
Siderophores - 
Iron uptake 
iuc Aerobactin  A Yes 
iutA Ferric aerobactin ExPEC A Yes 
chu 
Chu hemin uptake, outer membrane 
heme/hemoglobin receptor 
UPEC A Yes 
ent Ferrienterobactin  A Yes 
iroN IroN salmochelin receptor  A Yes 
ireA Siderophore receptor  B No 
irp2 Yersinia biosynthesis gene  B No 
Toxins 
pic Pic serine protease  A Yes 
sat Sat protease, Secreted auto transporter toxin  A Yes 
vat 
Tsh (vat) protease. Temperature sensitive 
hemagglutinin/vacuolating autotransporter 
UPEC A Yes 
hly Hemolysin   A Yes 
cnf1 Cytotoxic nectrotizing factor 1  A Yes 
Miscellaneous 
malX Pathogenicity island marker  C Yes 
hsp 
Uropathogen specific protein, type VI 
secretion system 
 C Yes 
yfcV Putative fimbrial-like adhesin protein UPEC E Yes 
fyA Pesticin/yersiniabactin receptor UPEC E Yes 
clbB/N Colibactin synthesis  B No 
cvaC Microcin V  B No 
fliC H7 flagelin  B No 
*Reference codes: A= VFDB [119]; B= Olesen 2017 [120]; C= Johnson 2019 [121], Hung 2019 [122] 
and Kanamori 2017 [123]; D= Johnson 2003 [114] and Hung 2019 [122]; E= Spurbeck 2012 [115] 
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2 AIMS 
2.1 OVERALL AIM OF THE THESIS 
The overall aim of this thesis is to investigate strategies for improving care of patients with 
bloodstream infections (BSI) caused by ESBL-producing Enterobacterales (EPE), 
particularly E. coli and K. pneumoniae (Figure 10). 
Figure 10. Overview of thesis aims. 
2.2 SPECIFIC AIMS OF INCLUDED STUDIES 
 
• To identify risk factors for community-onset EPE BSI and from these create a clinically 
useful, simple screening tool (Stockholm score) as an aid for decisions on empiric 
therapy (Study I). 
• To compare the diagnostic performance of the newly developed Stockholm score to that 
of a previously suggested score (Utrecht score) (Study I).  
• To evaluate the performance of 6-hour reading of disk diffusion inhibition zones and 
phenotypic tests for detection of ESBL- and carbapenemase-production for E. coli and 
K. pneumoniae (Study II). 
• To determine the clonal, serotype and plasmid diversity of an international collection of 
K. pneumoniae with production of the carbapenemase NDM-1 (Study III). 
• To explore the potential of using automated repetitive sequence-based PCR (rep-PCR) 
as a proxy for MLST to rapidly identify successful clones of K. pneumoniae (Study III). 
• To describe the molecular epidemiology of community-onset BSI caused by ESBL-
producing E. coli in Stockholm (Study IV). 
• To examine the association of virulence genes, resistance genes and clonality with 
severity of disease and source of infection in community-onset BSI caused by ESBL-
producing E. coli (Study IV). 
Patient with  
EPE BSI 
Early identification of patients at risk 
 improved initial therapy 
 
Study I 
Rapid susceptibility testing 
 Early correction of therapy 
 
Study II 
Molecular epidemiology 
 improved knowledge of virulence and spread  
of multidrug-resistant (MDR) clones 
 
Study III and IV 
 26 
3 METHODOLOGICAL CONSIDERATIONS 
For detailed accounts of the material and methods used, see the method section of each 
publication. Here general considerations for the choice of methods are described. In addition, 
the different methods for molecular epidemiology used in this thesis are also explained in 
detail and discussed, since the differences between them might not be clear for all readers. 
3.1 EPIDEMIOLOGY AND PREDICTION 
3.1.1 Case-control study (I) 
Study I was a retrospective case-control study with 277 cases with EPE BSI and 400 
matched controls from the source population of patients visiting the emergency department 
with a suspected severe infection with Gram-negative bacilli in the years 2012-2015 (Figure 
11). The source population was defined as patients ≥18 years old with a blood culture 
sampled at one of four emergency departments in Stockholm (Karolinska University Hospital 
in Solna and Huddinge, Södersjukhuset and Danderyd Hospital), admitted to hospital, and 
antibiotic treatment with an agent with activity against Gram-negative bacilli started within 
24 hours.     
Figure 11. Flowchart of Study I (illustration from publication). 
The choice of the source population in a case-control study is very important for the 
generalizability and possibility for application of the obtained results. The results are valid 
only for the population studied. This is especially important in the study of AMR bacteria. 
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3.1.1.1 The important choice of source population 
Special considerations are needed for study design regarding prediction of infections with 
AMR bacteria. The majority of prior studies on risk factors for ESBL BSI have compared 
patients with BSI caused by ESBL-producing bacteria to BSI caused by the same pathogen 
without ESBL-production [45]. However, this method might bias the results by 
overestimating the importance of previous antibiotic treatment [124, 125]. Patients who have 
received active antibiotics are less likely to have a bloodstream infection with a susceptible 
strain, since it would be inhibited by the treatment. This causes the exposure to antibiotic 
treatment to be less probable in the control group. On the other hand, if one uses the entire 
population of patients with BSI as the source population, there is a risk that an association 
detected is a surrogate marker for BSI with the pathogen in question, E. coli or 
Enterobacterales, depending on how cases are defined. A suggested alternative study-design 
is to compare cases with both source populations as was done in two studies by Rodriguez-
Baño et al. [51, 52]. Unfortunately, this approach increases the time and cost necessary for 
performing the study. 
Table 4 summarizes important differences between studies using a source population with 
patients with E. coli BSI versus patients with suspected infection with Gram-negative bacilli. 
As our aim was to develop a clinically useful risk score to guide empiric therapy, we chose to 
use all patients presenting at the emergency department with suspected Gram-negative 
infection as the source population.  
Table 4. Comparison of two alternative study designs of Study I.  
Variable 
Type of source population 
 
E. coli BSI                                         Suspected BSI with Gram-neg bacilli 
Cases 
ESBL-producing E. coli  
in blood culture 
ESBL-producing Enterobacterales (EPE) 
in blood culture 
Controls 
Non-ESBL-producing E. coli  
in blood culture 
Patients with suspected BSI caused by Gram-
negative bacilli who are admitted to hospital, 
without EPE in blood culture 
Generalizability 
Only patients with a positive blood 
culture with E. coli 
Patients with suspected BSI caused by Gram-
negative bacilli who are admitted to hospital 
Time after blood 
culture sampling 
20 - 48 hours 0 hours 
Disadvantages 
Overestimates the risk caused by prior 
antimicrobial treatment 
Only ESBL-EC, not other EPE studied 
Risk for dilution effects 
Prediction of EPE or Gram-negative BSI? 
Advantages Simple 
The population reflects the desired population for 
application of the results 
Approximate size of 
source population 
≈ 5,000 episodes 46,723 episodes 
Prevalence in the 
cohort of study I 
≈ 10% 0.59 % 
3.1.1.2 Matching variables 
In case-control studies controls preferably are randomly selected from the source population. 
Matching on strong confounders is a method frequently used to improve the efficacy of the 
study. Otherwise there might be little overlap between cases and controls so that the control 
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group would have to be excessive in size (e.g. if a study on dementia failed to match for age, 
the number of controls in the relevant age-groups would be too low). The matching variables 
must be corrected for in the statistical analysis, and the influence of the matching variables in 
themselves cannot be studied [126]. In Study I we matched and adjusted for hospital and 
year of blood culture sampling, since these factors were strongly related to the proportion of 
bacterial samples that were EPE.  
3.1.2 Cohort study (IV) 
In Study IV the cohort consisted of a subset of cases from Study I, patients with community-
onset BSI caused by ESBL-EC attending the emergency departments of Karolinska Hospital, 
Södersjukhuset and Danderyd Hospital 2012-2015 (Figure 12). The cohort design enabled 
studies of associations of patient characteristics and microbiological determinants with 
several different outcomes, including severity of disease, mortality, mode of infection, 
repeated BSI episodes and patients with a low risk for EPE BSI.    
Figure 12. Flowchart of Study IV (illustration from manuscript). LIS: laboratory information system. 
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3.1.3 Multivariable logistic regression (I, IV) 
In Study I and IV, multivariable logistic regression was used as the main statistical method 
to assess the relationship between the examined variables and the outcomes. In Study I 
randomly selected controls were matched for hospital and year, and the univariate logistic 
regression was adjusted for these two variables. In Study IV, there were no matching 
variables to consider, since the study was based on all patients in the cohort and there were no 
selected controls. Purposeful selection of variables to include in multivariable analysis was 
performed according to the steps described by Hosmer, Lemshaw and Sturdivant [127]. In 
short, this process included: 1) A careful univariate analysis. 2) Thoughtful selection of 
variables to include, considering a) clinical relevance b) a univariate/adjusted p-value of 
<0.20. c) avoiding inclusion of intermediate variables between the exposure and the outcome 
variable. 3) The model was fitted with all selected variables. The variables with the highest p-
value were removed, and a new model was fitted. 4) The new model was compared with the 
old model by post-estimation with the likelihood ratio test. If the new model was significantly 
different, the latest removed variable was reintroduced. 5) This process was continued until 
no further variables could be removed without a significant difference from the previous 
model. 
In Study IV there were several occasions with contingency tables with a zero cell, which is 
not possible to include in normal logistic regression. For some cases this problem was solved 
by combining groups, in other cases when there was no sensible group to combine with, 
univariate analysis was performed by Fisher’s exact test.   
3.2 EVALUATION OF DIAGNOSTIC METHODS 
3.2.1 AST-method evaluations (II) 
Study II compared the performance of rapid antimicrobial susceptibility testing (AST) with 
disk diffusion after 6 hours of incubation compared to standard 18 hours of incubation on 128 
isolates of E. coli and K. pneumoniae specially selected for representing a wide variety of 
resistance mechanisms.  
A microorganism is categorized as S, I or R by applying the appropriate breakpoint in a 
defined phenotypic AST-test system. At the time of the study the EUCAST definitions of the 
AST categories were S – Susceptible, I – Intermediate (since 1 January 2019 changed to 
“Susceptible, increased exposure”) and R – Resistant [128]. A description of the disk 
diffusion method is included in the introduction Section 1.4.2.  
When evaluating AST-methods, the results are reported as minor error (mE), major error 
(ME), very major error (VME), categorical agreement (CA) and essential agreement (EA), 
according to the definitions outlined in Table 5. 
The criteria for acceptable performance for approval of newly developed AST-methods are 
defined by ISO-standard and FDA [129, 130]. ISO recommends including at least 300 
isolates and that the collection should include as many unrelated strains representing different 
degrees of susceptibility as possible. FDA recommends 300 isolates plus an additional 75 
challenge isolates with MICs near breakpoints. When calculating the ME rate, the 
denominator used is the number of isolates tested susceptible with the reference method, and 
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for VME rate the denominator is the number of isolates tested resistant, according to both 
FDA and ISO.  
In Study II the reported ME and VME rates used the denominator total number of tested 
isolates, therefore these rates cannot be directly compared with the ISO/FDA criteria.  
 
Discrepancy rates are very dependent on the level of resistance of included isolates. If all 
isolates are highly susceptible or resistant, the discrepancy rates are naturally much smaller 
than if many borderline resistant isolates are included. With increasing levels of resistance, 
and the spread of new resistance mechanisms, AST methods are constantly being challenged. 
Methods with good performance when they were FDA approved might not be able to 
distinguish between borderline-resistant and -susceptible isolates. However, with increasing 
resistance rates correct grading of susceptibility is also increasingly important. When there 
are few therapeutic options left in MDR isolates, one might have to resort to using an 
antimicrobial despite acquired resistance to that agent.  
EUCAST changed the definition of the SIR-category on 1 January 2019, which will have 
some implications for future evaluations of AST-methods, see Section 5.2.3. 
3.2.2 Receiver operator characteristics (ROC) (I, II) 
ROC-analysis is a method for comparing the performance of two different diagnostic tests 
and identifying the appropriate cut-off of a diagnostic test. This is done by plotting the 
diagnostic test sensitivity (true positive rate) on the Y-axis, and 1-specificity (false positive 
rate) for each value of the test [131]. 
Figure 13 shows a hypothetical ROC-analysis comparing test A and test B. A cut-off set at 
the sensitivity-level of 0.90 corresponds to a specificity of 0.97 (1-specificity: 0.03) for test A 
and 0.75 (1-specificity 0.25) for test B. Thus, test A is a better performing test than test B. If 
only test B is available, the choice of cut-off is dependent on how the test will be used. For 
screening tests, most often a high sensitivity is sought and positive test results are then 
confirmed with a more specific test (often more complicated and expensive).  
Table 5. Definitions of terms in evaluation of AST-methods, according to ISO 20776-2 2007 and 
FDA 631 2009. 
ISO-
abbreviation 
  
Criteria for acceptable 
performance of AST-method 
Category Explanation ISO FDA 
VME  Very Major Error Report S when reference is R <3% a <3%a 
ME Major Error  Report R when reference is S <3% b ≤3%b 
mE Minor Error  All errors which includes I   
CA  Category Agreement  Correct SIR ≥90% ≥90% 
EA Essential Agreement 
Disk diffusion +/- 3mm 
MIC +/- 1 MIC-dilution 
- 
≥95% 
- 
≥90% 
Notes: ISO and FDA use the term “Discrepancy” instead of the in publications commonly used term “Error”. 
aVME rate based on the number of resistant organisms tested. Depends on the number of included resistant isolates.  
bME rate based on the number of susceptible organisms tested. 
  31 
Figure 13. Example of receiver operator characteristics (ROC) curve used in evaluation of diagnostic 
tests. 
ROC-analysis was used in Study I to calculate and compare the specificity and sensitivity of 
the Stockholm and Utrecht scores for prediction of ESBL-EPE BSI, and to assess if an 
alternative cut-off for the Utrecht score would improve the results. In Study II the method 
was used to compare 6-hour disk diffusion screening for CPE with meropenem and 
faropenem disks.  
3.3 METHODS USED FOR MOLECULAR EPIDEMIOLOGY (III, IV) 
Identifying different types of organisms within a species, typing, is important for local 
outbreak investigations and for global surveillance through monitoring of trends, evolution 
and spread of microorganisms. Typing is frequently applied for both foodborne pathogens 
and multi-resistant bacteria. Molecular typing methods have been in use for the last 30 years 
and the restriction-enzyme method pulsed-field gel-electrophoresis (PFGE) has long been 
considered the gold standard for species typing of E. coli and K. pneumoniae and many other 
species [132]. PFGE was especially useful in outbreak investigations since it had excellent 
discriminatory ability, good intra-laboratory reproducibility and was cost-effective, but the 
method was less useful for global molecular surveillance since comparisons between PFGE 
performed in different laboratories was not possible.  
Many other molecular methods for bacterial typing have been used but in recent years 
generally abandoned with the technological advance, increase in availability and decrease of 
costs of whole genome sequencing (WGS). These prior commonly used methods include 
amplified fragment length polymorphism (AFLP), random amplification of polymorphic 
DNA (RAPD), automated repetitive sequence-based PCR (rep-PCR), variable-number 
tandem repeat (VNTR), multilocus VNTR (MLVA), single locus sequence typing (for 
example spa-typing for S. aureus) and comparative genomic hybridisation with DNA 
microarrays. A detailed description of these typing methods is beyond the scope of this thesis 
and have been described elsewhere [132]. Only the methods used in the included studies are 
described in detail: multilocus sequence typing (MLST), rep-PCR and WGS-based analyses. 
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3.3.1 Multilocus sequence typing (MLST) (III, IV) 
For regional and global surveillance typing for common bacterial pathogens, the most 
suitable and widely used method is multilocus sequence typing (MLST) [133]. However, the 
discriminatory power is too low to be used in outbreak situations and local surveillance.  
The first MLST typing scheme was introduced in 1998 for Neisseria meningitidis, and the 
method was rapidly adapted to other species [132, 134]. MLST uses a set number, usually 
seven to eight, of conserved housekeeping genes that are present in all strains of the species. 
The genes were chosen based on their optimal intra-species variability for the purpose of 
following evolution and spread over time and space [135]. In traditional MLST (Study III) 
these genes are amplified with PCR, then the nucleotide base sequence is determined by 
Sanger sequencing technique. The obtained DNA-sequence of each housekeeping gene is 
compared by basic local alignment search tool (BLAST) to a database of previously 
sequenced isolates and assigned to an allelic number, if the sequence is previously known. 
New sequences are assigned a new allelic number and deposited in the database. The 
combination of the obtained seven allelic number are compared to previous allele-
combinations, and assigned to a present or new, sequence type (ST) serial number. Two 
isolates with the same ST have identical sequences in the seven housekeeping genes.    
For Klebsiella pneumoniae the Pasteur MLST database was used in Study III, which 
includes the seven housekeeping genes gapA, infB, mdh, pgi, phoE, rpoB and tonB. 
(http://bigsdb.pasteur.fr/ecoli/ecoli.html) [136]. 
For E. coli there are three different MLST-schemes using different housekeeping genes: the 
University of Warwick (Achtman) MLST, including the seven genes adk, fumC, gyrB, icd, 
mdh, purA, and recA (http://enterobase.warwick.ac.uk/species/ecoli/allele_st_search) [91], 
the Pasteur institute MLST database including the eight genes dinB, icdA, pabB, polB, putB, 
trpA, trpB, and uidA (http://bigsdb.pasteur.fr/ecoli/ecoli.html) [137] and one specialized for 
enterotoxigenic E. coli at the Michigan State University that includes the genes aspC, dpX, 
fadD, icd, lysP, mdh and uidA [138]. STs obtained by the different schemes were compared 
by Clermont et al. [138]. The University of Warwick scheme had the lowest resolution of the 
three schemes but seemed to be the most robust and had the most congruent results with 
whole genome sequence methods. The University of Warwick nomenclature is the most 
widespread and is the one used for in silico MLST of WGS-sequences in Study IV.   
From whole genome sequencing data, information can be extracted in silico for genes 
included in the traditional MLST, which now has become less labour intensive and cheaper 
than traditional MLST (see below). 
3.3.2 Automated repetitive-sequence-based PCR (rep-PCR) (III) 
The commercial automated repetitive-sequence-based PCR (rep-PCR) method DiversiLab 
(bioMérieux, Marcy d’Etoile France) was evaluated for NDM-1-producing K. pneumoniae as 
a part of Study III. This rep-PCR method (also called repetitive-element PCR) used PCR 
with primers for noncoding regions that are present in several separated regions interspersed 
in the bacterial genome [132, 139]. The regions in between the primers were amplified, 
which produced multiple PCR-products of different lengths, depending on the placing of the 
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primer-sequences in the genome. The amplicons were then separated by high-resolution chip-
based microfluidic capillary electrophoresis and detected and visualized as trees and virtual 
gel band-patterns through the product-specific software. The method was a rapid, less labour-
intensive method compared to PFGE and was found to be useful for primary identification of 
hospital outbreaks especially for Klebsiella species and Acinetobacter species, but for other 
species the discriminatory power was too low for outbreaks. Results should be confirmed 
with another method if isolates in an outbreak was assigned to the same type [132]. 
Production of the DiversiLab instrument and kits have been discontinued by the company 
bioMérieux and is no longer available [140]. A probable reason for this is the increased 
availability and reduced costs of microbial typing with whole genome sequencing. 
3.3.3 Whole genome sequencing (WGS) (IV)  
The classic sequencing method Sanger sequencing introduced in 1977 was based on 
incorporating fluorescent-labelled terminating base pairs in in vitro DNA replication [141]. 
Sanger sequencing is limited to sequences < 1,000 bases in length and is useful for individual 
genes, but not for entire organism genomes. An E. coli-genome consists of about 4,500,000 
base pairs. Sanger sequencing was used for MLST genes in Study III. Sequencing methods 
have been rapidly developed in the last 15 years and the cost of sequencing dropped rapidly 
between 2007 and 2015, with the introduction of new powerful high-throughput sequencing 
methods [142].  The cost of sequencing is further reduced by centralizing sequencing 
instruments and bioinformatic knowledge for both human and microbial genome sequencing 
in institutions such as Science for Life Laboratory (SciLifeLab, Solna, Stockholm). 
There are several different next-generation sequencing (NGS) technologies that can be used 
for sequencing of entire genomes called whole genome sequencing (WGS). These methods 
include Ion Torrent, Illumina, Pacific Biosciences (Pac Bio) and Oxford Nanopore [141]. In 
Study IV Illumina HiSeq 2500, placed at the Science for Life laboratory (SciLifeLab), was 
used for WGS. Illumina uses a sequencing-by-synthesis method which detects release of 
fluorescent labels from incorporated nucleotides to determine the sequence [141]. The main 
advantages of Illumina sequencing are a low error rate, massive throughput capacity, with 
hundreds of microbial genomes sequenced simultaneously and low cost per output. 
Disadvantages are longer run time and short reads, which limit the possibility for de novo 
assemblies and plasmid detection. 
Short reads of DNA sequences generated by Illumina are assembled by mapping to a 
reference genome (reference-based mapping) or de novo assembly, which gives the entire 
gene sequence of the isolate. Although the obtained sequence is referred to as the “whole 
genome”, it is not exactly a “true” genome, as errors in the sequence can arise in several parts 
of the process, including during the extraction-process of DNA, contamination, sequencing 
process errors, and assembly errors. To minimise these errors, several quality control checks 
are done during the process.  
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Table 6. Main steps of WGS and location of work/software used in Study IV.   
No. Step Location/Software used 
1 Extraction of DNA Karolinska University Laboratory 
2 Library preparation SciLifeLab 
3 Sequencing generating Illumina short reads SciLifeLab 
4 De novo assembly with SPAdes v3.1 
Assembly polish and quality assurance steps  
microSALT pipeline and Enterobase 
 
5 Detection of  
- Virulence genes  
- Resistance genes 
 
microSALT + Selected virulence genes  
microSALT + Resfinder 
6 Phylogenetic analysis 
- SNP 
- cgMLST + Hier CC 
- MLST 
Enterobase + GrapeTree + iTOL 
 
 
3.3.3.1 Quality of the extraction process 
The influence of the extraction process on the quality of sequences was illustrated in the work 
with Study IV. The initial extraction of DNA was performed with MagnaPure 96 (MP96, 
Roche, Basel, Switzerland) which is a standard platform for DNA-extraction before PCR. 
However, the quality control of the sequencing reads showed unexpected low read depth. The 
quality of a sequence is measured in sequence read depth, i.e. the average depth of 
overlapping reads at any locus. There are not yet established thresholds for quality control, 
but an average read depth of >30x is generally considered as adequate quality [141], while 
others recommend a minimum read depth of >30x [76]. The initial sequencing after extraction 
with MP96 yielded many isolates with low quality reads, with 10x coverage less than 90%, 
and several isolates which failed in MLST allelic calling in Enterobase, mainly for fumC but 
also for other MLST genes. For this reason, 54 isolates were re-sequenced with extraction by 
EZ1 (Qiagen, Hilden, Germany). Both methods use magnetic bead technology but the EZ1 
has protocols developed for the needs of WGS. The quality of the genome-sequences finally 
used in Study IV clearly varied depending on the extraction method used. In total 58 isolates 
were extracted with EZ1, of these 97% had a 30x coverage rate over 97% (corresponds to 
minimum read depth of >30x) and 100% had both 30x and 50x >50% (corresponds to 
average read dept of >30x). For the 220 isolates that were extracted with MP96, only 38% 
had a 30x coverage rate over 97%, and 97% had 30x >50% while 79% had 50x >50%. 
3.3.4 Core genome multilocus sequence typing (cgMLST) (IV) 
Core genome multilocus sequence typing (cgMLST) is a method for bacterial typing which is 
more discriminatory than traditional MLST but based on the same principle. Instead of using 
7 housekeeping genes identified by PCR (or in silico from WGS), cgMLST uses in silico 
detection of >2,000 core genome genes, which optimally are present in all, or at least most 
isolates of a species. The Enterobase scheme for cgMLST includes 2,513 genes for E. coli 
[143]. Each gene is assigned an allelic serial number and the 2,513 allelic numbers are used 
to obtain a serial core genome sequence type (cgST) number. Two isolates with identical 
cgST have the same gene sequence in all the 2,513 genes. There are several schemes of 
cgMLST on different platforms for E. coli and an international standard is lacking.  
The drawback of cgMLST is that not all isolates have all genes. Deletions and insertions can 
give rise to distortions in the phylogenetic relationships. The more isolates that are tested, the 
fewer genes all isolates have in common. However, cgMLST is a powerful method, rapid 
  35 
after the initial designation, needs less bioinformatic power than single nucleotide 
polymorphism and can easily produce trees with >10,000 genomes [143, 144].  
Woksepp et al. demonstrated the usefulness of a cgMLST scheme (SeqSphere+, Münster, 
Germany) in a nosocomial outbreak of ESBL-EC of ST131 in Sweden and obtained 
comparable results as with PFGE and SNP [145]. 
The normal MLST nomenclature is useful in communication about high-risk clones and 
changes in global epidemiology. However, the cgST types are not sensible to use in 
communicating clones, not even in outbreak situations. Since more than 2,000 genes are 
included, it is likely that mutations occur in some isolates within the outbreak, and they will 
then have different cgST numbers. As the cgST numbers are allocated in the order of 
appearance, the cgST number in itself does not give any information about the relatedness of 
isolates. Instead the number of allelic differences between the genomes in question, 
preferably presented as a phylogenetic tree, is more informative. 
3.3.5 Single nucleotide polymorphism phylogeny (SNP) (IV) 
Single nucleotide polymorphism, SNP-analysis of WGS-genomes has become a common and 
useful method for outbreak and transmission analysis. This is performed through reference-
based mapping of either reads or assembled contigs. Repeated regions, regions that are 
missing in a certain proportion of the genomes (typical threshold 5%) and regions that are the 
same in all compared genomes are filtered out. The remaining positions contain an SNP in at 
least one of the compared genomes. The SNP-differences can be displayed as a matrix 
(Figure 14 E) between the compared genomes or as phylogenetic trees. Phylogenetic trees, 
for both SNP and cgMLST are normally obtained through one of several maximum 
likelihood tree algorithms, such as the randomized accelerated maximum likelihood program 
(RAxML) [146]. 
A limitation with SNP-based phylogeny is that the result varies due to the number and types 
of genomes included. It works best when only including a few, closely related genomes with 
a closely related reference genome. If more distantly related genomes are included in the 
analysis, the number of mapped bases decreases, and the risk of mis-mapping increases [147].    
3.3.6 Comparison of MLST, cgMLST and SNP 
A comparison of the usefulness of MLST, cgMLST and SNP-analysis is provided in Table 7. 
The outputs and results of the different methods have been applied on the same set of 
genomes in Figure 14 A-E. In this comparison the same 40 genomes are included in all 
analyses. Six are reference genomes, and the rest are from 16 patients with repeated episodes 
of ESBL-EC BSI from Study IV. Repeated isolates from the same patient but sampled >30 
days apart are considered to have an epidemiological relationship. Each patient is coloured in 
the same colour in all figures. For 15 of the 16 patients, both episodes were caused by closely 
related isolates, and all methods give the same result, but with different resolution. In Figure 
A, Achtman 7-gene MLST assigns repeated episodes to the same ST, but within-ST 
relationships cannot be determined. With cgMLST in Figure B it is clear that isolates from 
the same patient are more related to one another than to isolates from other patients within the 
same ST. This is seen for ST131, ST405 and ST354. However, each node has an individual  
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A. Achtman 7-gene MLST, minimal spanning tree. Distance on branches are number of allelic 
differences. Node size is relative to number of isolates. Number on node refers to ST. 
B. Enterobase cgMLST, minimal spanning tree. Distance on branches are number of allelic 
differences. Dotted branches (length > 500) are shortened to facilitate visualisation. Node sizes are 
relative to number of isolates. Number on node refers to ST (Achtman 7-gene MLST). 
Figure 14. A-D. Comparison between different molecular typing methods. The phylogenetic 
relationship between the same 40 genomes (34 isolates from 16 patients from study IV and 6 reference 
genomes) are shown. Isolates from the same patient are the same colour in all figures according to 
legend. White nodes are reference genomes All trees are made with Enterobase Grape Tree. E. SNP-
matrix for the four patients with ST131 clade C1.  
Color code:  
Patient id [# isolates] 
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C. Maximum likelihood SNP-dendrogram. Scale 
of branch length is the number of substitutions 
per site. Labels refer to ST (7-gene MLST).  
D. Minimal spanning tree based on the same 
SNP-data as in figure C. Number on branch 
refers to number of substitutions per site. Dotted 
branches are shortened to facilitate 
visualisation. 
 
 
 
E. Example of SNP-matrix. Matrix showing the number of SNPs between 9 isolates from four patients 
with ST131 clade C1. Headings are coloured with the same colour as in figure A-D. Cells in matrix 
are toned according to number of SNPs (White 0-10 SNPs, Dark brown >500 SNPs). 
Jul 2015 Dec 2014 Aug 2013 Mar 2013 Dec 2014 Jan 2013 Feb 2014 May 2014 Apr 2012
EF542 EF479 EF347 EF312 EF481 EF301 EF411 EF435 EF215
EF542 0 4 414 372 368 362 1295 1299 1292
EF479 4 0 412 370 366 360 1293 1297 1290
EF347 414 412 0 44 58 58 1272 1277 1269
EF312 372 370 44 0 22 16 1230 1235 1227
EF481 368 366 58 22 0 12 1226 1231 1223
EF301 362 360 58 16 12 0 1220 1225 1217
EF411 1295 1293 1272 1230 1226 1220 0 15 7
EF435 1299 1297 1277 1235 1231 1225 15 0 8
EF215 1292 1290 1269 1227 1223 1217 7 8 0
Patient 2
Patient 5
Patient 4
Patient 3 Patient 2 Patient 5 Patient 4
Patient 3
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Table 7. Comparison of MLST, cgMLST and SNP for epidemiological typing of E. coli. Table 
compiled from references [141, 144, 145, 147, 148]. 
 
 
Comparator MLST 
cgMLST  
(Enterobase) SNP 
Discriminatory power Low High  High 
Suggested relatedness 
threshold in outbreak 
settings  
                    Related 
                    Not related 
NA 
NA 
≤10 allelic differences 
>100 allelic differences 
≤10 SNPs 
>100 SNPs 
Description 
7 conserved house-
keeping genes 
2,513 core genome 
genes, present in most 
isolates of a species 
Genomes are 
mapped to 
reference. Repeat 
regions, regions 
that are missing in 
≥5% and bases that 
are the same in all 
compared isolates 
are filtered out 
Method for dealing 
with recombination 
Only conserved genes 
are included, 
recombination in 
other parts of the 
genome does not 
affect the result  
Recombination events 
can occur and somewhat 
distort phylogenetic 
relationships. 
Recombinant regions will 
be collapsed into a 
smaller number of allelic 
changes. Less impact of 
recombination in 
cgMLST than wgMLST 
Only SNPs in 
positions present in 
all compared 
genomes are 
compared 
Speed With WGS, high 
Very rapid to perform 
comparisons after initial 
assignment of alleles 
Slow 
Capacity  With WGS, high 
High, >20,000 genomes 
have been compared in 
the same analysis 
Works best with 
few closely related 
strains (preferably 
within the same or 
closely related 
STs) with a closely 
related reference 
genome 
Interlaboratory 
Standardization 
High, the same 
database for MLST 
are used. Only quality 
of sequencing varies 
High, if the same 
cgMLST scheme is used. 
There are several 
different platforms 
Low, somewhat 
different results 
depending on 
included genomes 
Standardization and 
usefulness of 
nomenclature 
High, global lineages 
have the same ST 
Standardisation is high 
within the same cgMLST 
scheme. But resolution is 
too high for cgMLST-
names to be useful 
No nomenclature 
Main area of 
usefulness 
Global epidemiology 
Nomenclature 
Sequence types 
Outbreaks  
Global epidemiology 
Phylogenetic trees  
Outbreaks  
SNP-matrix  
Phylogenetic trees 
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cgMLST number (not shown). The number of allelic differences between isolates from the 
same patient is small, often <10 alleles. The same is clear from the SNP dendrogram in 
Figure C but is less obvious when the SNP is presented as a minimal spanning tree (Figure 
D). The individual number of SNPs that differs between included genomes can conveniently 
be displayed as a matrix (Figure E). 
The differences between the methods are presented in Table 7. In summary, the sequence 
types obtained by MLST, which is the least discriminatory method, are most useful as a 
common nomenclature for global surveillance of high-risk clones and association of different 
STs with resistance genes, virulome and infection types. cgMLST and SNP-analysis can both 
be used for outbreak analysis but are more difficult to compare between analyses. Results 
obtained by different cgMLST schemes cannot be compared. SNP is at its best when applied 
on a small number of closely related isolates within a suspected transmission event, while 
cgMLST has potential to elucidate detailed phylogenetic relationships in comparisons that 
include a high number of genomes. 
However, recombination and horizontal gene transfer, is a common cause of distortion of 
phylogenetic relationships and creates pitfalls for all methods. In order to minimize the 
impact of recombination, a subset of genes/single nucleotide variants are used, but this 
problem is necessary remember, and the “true” phylogenesis is impossible to obtain [91]. 
3.3.7 Detection of virulence and resistance genes (IV) 
For identification of virulence genes in Study IV, a selection previously described virulence 
genes with association with ExPEC, was compiled and analysed with Basic Local Alignment 
Search Tool (BLAST) through the in-house bioinformatic pipeline microSALT 
(https://github.com/Clinical-Genomics/microSALT), for detection of 108 virulence genes in 
the 278 genomes. For some genes the web tool NCBI nucleotide BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) was used for further characterisation and trouble-
shooting. For resistance gene detection the resistance database of the microSALT pipeline 
was used, which in turn used the ResFinder database v2.1 [149]. 
Establishing presence or absence of a gene in a WGS genome has some inherent difficulties. 
For sequencing methods that generates short-end reads as the method used in Study IV, 
Illumina sequencing, the following assembly of the short reads can cause difficulties. 
Depending on settings in the assembly method, contigs can be truncated at different sites. If a 
gene of interest is divided between two contigs, the gene will not be detected. Additionally, 
where to define the threshold for the similarity of a gene (identity %) needed to predict the 
presence of a gene is not obvious and thresholds must be adapted to the context. Some genes 
have conserved sequences and do not show much variation, since a mutation might alter the 
function completely. Other genes, e.g. surface exposed virulence genes, have a high allelic 
diversity, but still the same function. An example is fimA which is under constant pressure to 
diversify to avoid the immune system [150]. Hence it might be appropriate in some 
circumstances to have a conservative strict identity threshold and in other cases to have a 
permissive threshold. 
For detection of resistance genes, the cut-off used in microSALT pipeline Study IV was 97% 
identity and 90% gene coverage, the same as is used in clinical samples. For virulence genes, 
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the cut-off for identity was initially set at 90% identity and 90% gene coverage, but this 
turned out to be too high, for some genes with high allelic diversity. Hence the cut-off was 
lowered to 80% identity and 80% gene coverage. There is no international consensus for 
which cut-off to use for different genes, but the 80/80 cut-off was applied previously for 
detection of virulence genes in ESBL-producing ExPEC [123]. 
3.4 SOFTWARE 
Microsoft Access database was used to collect and store data for Study I and IV. Microsoft 
Excel was used for data storage in Study II and III and for calculations in all studies. Stata 
IC statistical software: release 13 (StataCorp LP, College Station, TX) was used for statistical 
calculations in Study I, II and IV.   
In Study IV several web resources for analysis of genomic sequences and graphical 
illustrations was used: Enterobase (https://enterobase.warwick.ac.uk/) [143, 144], the 
Enterobase embedded function GrapeTree software [151] and the Interactive tree of life 
(iTOL) (https://itol.embl.de/) [152]. 
In Study III, BioNumerics (Applied Maths, Sint-Martens-Latem, Belgium) was used for 
visualisation of minimal spanning tree.  
3.5 ETHICAL CONSIDERATIONS 
The collection of clinical data in Study I and IV was performed by review of medical records 
of the included patients. This inevitably involves a violation of patient privacy, as sensitive 
information will be collected and stored. Patient consent was not sought, instead permission 
was sought and obtained from the Regional Ethical Review Board in Stockholm (Dnr 
2014/277-31). 
From a utilitarian perspective, the ethical conflict is between the principle of the individual’s 
right to informed consent compared to the medical research value for the society and future 
patients. However, informed consent was deemed not possible since some of the patients 
included in the study were deceased at the time of the study. The value of the medical 
research obtained by the study is significant. By identifying risk factors for community-onset 
bloodstream infections caused by EPE, the study has resulted in knowledge that will improve 
empiric therapy for patients with EPE BSI. The new knowledge will also help avoid 
unnecessary broad-spectrum antibiotic treatment, and thus contribute to minimizing further 
antibiotic resistance development. Additionally, our understanding of the epidemiology and 
virulence of ESBL-EC in BSI has increased.   
All data were handled strictly confidential and identities were pseudonymized.  The key was 
kept separately in a password protected file, and only the investigators had access to the key. 
Study II and III were in vitro studies with bacterial strains without attached patient metadata. 
Although the bacterial isolates originated from human infections, what was stored and used 
were solely bacteria, and no human DNA or tissue remained. Thus, the strains were 
completely unrelated from their origin. No humans or animals were harmed. As a general 
rule, bacterial isolates are exempted from ethical permissions.  
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4 RESULTS 
4.1 STUDY I 
Prediction of bloodstream infection caused by extended-spectrum beta-lactamase-producing 
Enterobacterales in patients with suspected community-onset sepsis. 
The dilemma at hand when choosing empirical therapy for patients with suspected serious 
infections at admittance at the emergency department, is the need for prompt appropriate 
therapy for the causing microorganism, but at the same time avoiding overuse of broad-
spectrum antibiotics, which causes selection of even more resistant bacteria and further fuels 
the evolution of AMR bacteria. The aim of Study I was to develop a simple prediction score 
for EPE BSI to facilitate this choice at the emergency department, and to evaluate a 
previously published, complex prediction score, which we called the Utrecht score [153].  
Study I was performed as retrospective case-control study, set in Stockholm during 2012-
2015 (Figure 11). The final multivariable logistic regression model (summarized in Table 8) 
identified three major risk factors that seemed promising for use in a score, any prior EPE-
positive culture, a recent prostate biopsy and prior healthcare abroad. These were combined 
to form the Stockholm score which was compared to the Utrecht score when applied on the 
cases and controls.  
Table 8 Final multivariable prediction model of EPE BSI. Adapted from Study I.  
 
 
Risk factor 
Controls 
n=400  
(%) 
EPE BSI 
n=277  
(%) 
Multi-
variate 
OR P-value 
Any prior EPE-positive culture 3 33 19.1 <0.001 
Prostate biopsy ≤30 days 1 14 22.2 <0.001 
Prior healthcare abroad ≤6 months 2 6 3.9 0.016 
Age category 
    
<40 11 3 1.0  (Ref.) 
40-49 7 7 3.0 0.047 
50-59 9 15 2.8 0.045 
60-69 19 32 3.3 0.011 
70-79 27 21 1.6 0.317 
≥80 28 22 1.6 0.352 
Suspected diagnosis at admission 
    
Unknown 33 25 1.0 (Ref.) 
Abdominal 9 6 1.0 0.998 
LRTI 23 7 0.4 0.005 
SSTI 5 1 0.1 0.015 
UTI 26 60 2.6 <0.001 
Other infection 5 1 0.5 0.350 
SOFA-score 
    
0-1 39 29 1.0 (Ref.) 
2-3 38 34 1.5 0.086 
4-5 15 21 2.1 0.014 
≥6 9 17 4.0 <0.001 
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The final source population (estimated size 46,723 episodes) consisted of patients admitted to 
hospital with a community-onset suspected Gram-negative infection (i.e. who were given 
empirical treatment with an antibiotic agent with activity against Gram-negative bacilli). The 
estimated prevalence of EPE BSI, which we aimed to predict, was 0.59%. At first thought, 
this might sound surprisingly low. However, the explanation for the low prevalence in the 
population in question is that only about 15% of sampled blood cultures yield a positive 
result. Out of positive bottles 20% grow E. coli, an additional 5-10% grow other members of 
the Enterobacterales group and 10% of the E. coli are ESBL-producing.  
The consequence of the low prevalence is that the specificity of a score becomes very 
important for the number needed to treat (NNT). The predictors included in the Stockholm 
and Utrecht scores are outlined in Table 9 and their performance in Table 10. 
Table 9. Comparison of the included predictors in the two prediction scores.  
The two scores had similar sensitivity, Stockholm score 50% versus 54% for the Utrecht 
score, but the specificity of the Stockholm score was much higher, 96% compared to 77%. 
Figure 15 shows a ROC-comparison of the two scores and the individual predictors in the 
Stockholm score. The difference in specificity causes a great difference in the positive 
predictive value, 6.2% for the Stockholm score, and 1.4% for the Utrecht score. However, 
since the prevalence in the population is only 0.59, the numbers of patients needed to be 
treated, in order to treat one patient with EPE BSI with appropriate treatment, are quite high.  
If one uses a strict application of each score and thus treats all patients with a positive score 
with meropenem, the number needed to treat (NNT) can be calculated. In the following 
section, the definition of NNT is the number of patients (with and without EPE BSI) that 
would need to be treated in order to treat one patient with EPE BSI, with a strict application 
of each score. This concept is similar to, but not the same as, the NNT usually reported in 
randomized controlled trials. NNTALL (refers to all patients in the source population) would 
be 16 for the Stockholm score (to treat the 139 EPE BSI-cases that were positive for the 
Stockholm score, 2,103 patients without EPE BSI would have to be treated with meropenem, 
in total 2,242 patients treated). For the Utrecht score NNTALL would be 74 (149 EPE BSI 
cases and 10,863 cases without EPE BSI.).  
Two components of the Stockholm score, prior EPE-positive culture and prior healthcare 
abroad, are already recognized risk factors for EPE infection, which many infectious disease 
specialists and ED doctors already take into consideration when choosing empirical therapy. 
This means that the benefit of implementing such a score might be limited. We therefore 
compared a hypothetical strict use of the score with the empirical therapy the patients actually 
Predictor 
Stockholm 
Score 
           
Predictor 
Utrecht  
Score 
Any prior EPE-positive culture 1  Prior EPE-positive culture <1 year 100 
Prostate biopsy <30 days 1  Suspected UTI 50 
Prior healthcare abroad <6 months 1  Suspected pneumonia -50 
The Stockholm score is positive  
if the sum is ≥1 
 Immunocompromized 25 
 Any use of antibiotic <2 months 25 
   Age per year Age 
   The Utrecht score is positive  
if the sum is ≥120 [153] 
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received. Improved therapy for cases was defined as appropriate therapy started more than 24 
hours earlier with application of the score. For controls the impact of the score was measured 
as a change of therapy from any other treatment to meropenem. For the Stockholm score, a 
strict application on the included patients would have meant that 14% of cases would have 
received improved therapy but 3% of patients without EPE BSI would have been given 
meropenem instead of another agent, corresponding to a number needed to treat 
(NNTIMPROVED) of 39 for improved therapy.  For the Utrecht score, 19% of cases would have 
received improved therapy, but 21% of the population would have been given meropenem, 
NNTIMPROVED would be 182 patients.  
Table 10. Summary of the overall performance of the two prediction scores 
 
Stockholm score Utrecht score 
Sensitivity 50.2% 53.8% 
Specificity 95.5% 76.8% 
Positive predictive value (PPV) 6.2% 1.4% 
Negative predictive value (NPV) 99.7% 99.6% 
Number of cases with a positive score 139 149 
Estimated no. of controls with a positive score  
in the source population 
2,103 10,863 
Number needed to treat (NNTALL)A 16 74 
ANNTALL: Total number of patients that need to be treated to treat one patient with EPE 
BSI, with a strict application of the score, regardless of the empirical treatment that de 
facto was given. 
If all patients with a positive score had been given meropenem empirically 
 Stockholm score Utrecht score 
Cases (EPE BSI) with improved treatmentB    
Proportion of cases in study 14% 19% 
No. of patients in the source population  40 53 
Controls (no EPE BSI) with changed treatment   
Proportion of controls in study 3% 21% 
Estimated no. of patients in the source population  1,518 9,578 
Number needed to treat (NNTIMPROVED)C 39 182 
BImproved treatment: appropriate therapy started >24 hours earlier with application of 
score compared to what de facto was given. 
CNNTIMPROVED: NNT to improve therapy compared with what de facto was given.  
 
Patients de facto treated with meropenem as empirical treatment 
 Cases Controls 
Proportion (no.) treated with meropenem in study  25% (68) 8% (30) 
Estimated number of patients in the source 
population 
68 3,504 
 
The second important finding of the study was that a prior EPE-positive culture is the most 
important risk factor for EPE BSI in community-onset gram-negative infection, and that the 
time passed since the latest prior EPE-positive culture is important for the risk (Figure 16). 
The more recently the culture is taken, the higher odds ratio for EPE BSI, but the increased 
risk remains regardless how long time has passed since the sample was taken. A recent 
culture (sampled 8 days-3 months before the blood culture) has an odds ratio (OR) of 32.8 
compared to having no prior EPE-positive culture, while the OR for a sample taken >2 years 
before was 8.4. There was no statistically significant difference between a prior EPE-positive 
culture in a clinical sample or in a faecal screening-sample. 
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Figure 15. ROC-comparison between the Utrecht score, the Stockholm score and the three individual 
predictors included in the Stockholm score. The blue arrow indicates the Utrecht score cut-off at 
≥120. First episodes, n=677. 
 
 
Figure 16. Time from latest prior EPE-positive culture to date of blood culture. Bars show the 
proportion of all cases/controls that have a prior EPE-positive culture, coloured by sample type. 
Numbers over the bars represent ORs from logistic regression for each time-category compared with 
having no prior EPE-positive culture, adjusted for matching variables. Stars indicates the statistical 
significance-level of the OR. Graph adapted from Study I.  
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4.2 STUDY II 
Rapid EUCAST disk diffusion testing of MDR Escherichia coli and Klebsiella pneumoniae: 
inhibition zones for extended-spectrum cephalosporins can be reliably read after 6 h of 
incubation.  
4.2.1.1 Development of inhibition zones over time 
We programmed the BD KiestraTM total lab automation system to photograph AST agar 
plates at repeated times during incubation (at 5, 6, 7, 12 and 18 hours) which made it possible 
to follow the development of inhibition zones over time. The isolates tested were overnight 
cultures from frozen isolates of ESBL-producing, carbapenemase-producing and wild-type E. 
coli and K. pneumoniae.  
 
       
 
      
 
Figure 17. Development of inhibition zones over time. A) Photograph of the same disk diffusion plate 
after 6 hours and 18 hours of incubation photographed with BD Kiestra TLA. B) Development of 
inhibition zones over time for cefotaxime and trimethoprim-sulfamethoxazole. C) Histogram of 
meropenem with 6-hour reading (plum) compared to 18-hour EUCAST reading (blue).  
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At 5 hours of incubation, inhibition zones were difficult to read. In the final publication we 
compared 6-hour Kiestra-reading to 18-hour standard EUCAST manual reading. 
As is shown in Figure 17, the inhibition zones for wild-type isolates typically increase in size 
over time, while the inhibition zones of resistant isolates become smaller. This results in less 
separation between susceptible and resistant isolates when inhibition zones are read after a 
short incubation time. This trend was true for all tested antibiotics, although the effect was 
more pronounced for meropenem and trimethoprim-sulfamethoxazole. The consequence is 
that adapted breakpoints for each reading time and for each species is necessary to avoid 
errors in interpretation.  
4.2.1.2 Performance of rapid disk diffusion compared to standard disk diffusion 
For cefotaxime the category agreement was excellent, 98.7%, even when standard EUCAST 
breakpoints were applied, with no major errors and no very major errors (Figure 18). 
However, for most other antibiotic agents, there were unacceptably many errors when using 
standard EUCAST breakpoints (Table 11). These errors could to a large extent be eliminated 
for cefotaxime, ceftazidime, piperacillin/tazobactam, meropenem, ciprofloxacin and 
gentamicin, by using the adapted tentative breakpoints suggested by Jonasson et al. at the 
time of study [90]. The only error that remained was one isolate with a minor error for 
meropenem.          
 
 
Figure 18. Correlation between rapid AST inhibition zone reading at 6 hours with standard EUCAST 
reading at 8 hours for cefotaxime. EUCAST breakpoints applied to both readings are shown as lines 
(solid line, R/I breakpoint; dashed line S/I breakpoint.) The numbers refer to the number of 
observations for each data point. Results within the grey shaded area are classified as uncertain 
according to the tentative 6-hour reading breakpoints available at the time of study, these results 
should not be reported. Figure from Study II.    
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Table 11. Performance of selected antimicrobials with standard EUCAST breakpoints and 
breakpoints adapted for 6-hour reading available at the time of study. Table adapted from Study II. 
 
Cefotaxime 
Cipro-
floxacin 
Piperacillin-
tazobactam Meropenem 
EUCAST 18h breakpoint  
≥S/<R (mm) 
22/17 22/19 20/17 16/22 
RAST adjusted breakpointA  
≥S/<R (mm) 
22/16 22/17 21/15 25/17 
Errors with EUCAST 18h 
1.3% mE 11% mE 15% mE  
  0.7% MEB 
12% mE 
    0.7% VMEB 
Errors with adjusted bp 0% 0% 0% 0.7% mE 
Adjusted breakpoints for Rapid AST always have ATU - category – do not report 
Proportion of results that fall 
into ATU  
4% 15% 33% 20% 
ATentative breakpoints available at the time of study. 
BAll reported errors are proportions of all tested isolates. 
4.2.1.3 Performance of rapid tests for detection of ESBL and carbapenemase-production 
The ROSCO Diagnostica ESBL confirm kit 98011 (ceftazidime/ceftazidime+clavulanic acid 
and cefotaxime/cefotaxime+clavulanic acid), ROSCO KPC/MBL, MAST CAT-ID disk and 
the EUCAST disk diffusion meropenem-screening breakpoint for detection of CPE were also 
evaluated. These tests were more difficult to read at 6 hours, than the normal AST. For the 
ROSCO Diagnostica ESBL confirm kit, 6-hour reading had an overall sensitivity of 87% and 
a specificity of 98% (negative tests were inconclusive due to cefoxitin-resistance since this 
indicates the presence of AmpC for which an alternative test is needed). For 6-hour reading 
of the carbapenemase detection tests the overall sensitivity was low, especially for OXA-48-
producing isolates, and some misidentifications occurred. 
The conclusion was that ROSCO Diagnostica ESBL confirm kit can be read at 6 hours in 
isolates lacking cefoxitin-resistance, but that for accurate detection of carbapenemase-
production the full 18 hour of incubation is needed. 
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4.3 STUDY III 
Diverse sequence types of Klebsiella pneumoniae contribute to the dissemination of  
blaNDM-1 in India, Sweden, and the United Kingdom.  
A total of 39 K. pneumoniae isolates carrying the metallo-β-lactamase- (MBL) gene blaNDM-1 
were characterized in Study III, with the aim to identify if there was a domination of a 
single, or a few, successful clones or if the gene was widespread within different sequence 
types, and to evaluate if the DiversiLab typing method could be used as a rapid proxy method 
for MLST. 
At the time of the study, this carbapenemase-gene was recently identified, the first description 
occurred only three years earlier [154]. Isolates carrying this gene are often extremely multi-
drug resistant, in many cases only susceptible to last-resort antibiotics such as colistin.  
The included isolates originated from various sample types from India (two cities, Chennai 
and Haryana), the United Kingdom and Sweden. They belonged to 16 different sequence 
types and ST14 (13 isolates) was the most common and was found in samples from all three 
countries. Out of these, 10 were from the same hospital in Chennai and might partly reflect a 
hospital transmission event. All ST14 isolates carried the K2 serotype, which is associated 
with invasive disease. Other sequence types with more than two isolates were ST11, ST149, 
ST231 and ST625. None of the virulence genes allS, rmpA or wcaG were detected in any of 
the isolates. 
The blaNDM-1 gene was found on several different broad-range plasmids that can easily be 
transferred between species (IncA/C, IncL/M, IncN, IncHI1) and on the narrow-range 
plasmid IncF (IncFrepB). In 9 of the ST14 isolates blaNDM-1 was found on more than one 
plasmid type in the same isolate. The plasmid replicon type was untypable in 11 isolates.  
Typing by the DiversiLab automated repetitive-sequence-based PCR method (described in 
the methods section) generated results consistent with sequence types obtained by MLST. 
However, for hospital transmission investigations, within the same ST/DiversiLab-type a 
more discriminatory method such as PFGE or WGS might be needed. 
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4.4 STUDY IV 
ESBL-producing E. coli causing community-onset bloodstream infection and the association 
of bacterial clones and virulence genes with septic shock. 
From the cases with community-onset bloodstream infection studied in Study I, the subset of 
patients with growth of an ESBL-producing E. coli in the blood culture were selected for 
further analysis in Study IV. A total of 278 isolates from these 260 patients with ESBL-EC 
BSI were submitted to whole genome sequencing. Association of selected ExPEC virulence 
genes, resistance genes and sequence types with severity of disease and mode of infection 
was sought in multivariable analysis taking patient characteristics into account on the 260 
first-episode isolates. Isolates from repeated episodes were analysed separately.   
The globally successful high risk-clone ST131 was the dominant clone (47% of isolates), as 
expected (Figure 19). The fluoroquinolone-resistant and blaCTX-M-15-associated ST131 
subclade C2 comprised 30% and subclade C1 11%. Other common sequence types were 
ST38 (7%), ST648 (6%), ST10 (4%) and ST405 (4%). 
The overall all-cause 30-day mortality was low (6.5%), compared to other similar studies.   
Septic shock or death within 3 days was used as the primary outcome variable as a measure 
of severe initial disease and affected 27 patients (10%). In multivariable logistic regression, 
the factors most strongly associated with septic shock were a patient history of hematologic 
cancer or prior transplantation and detection of the virulence gene iss in the E. coli (Table 12 
and Figure 19). The product of the gene iss, increased serum survival, is an outer membrane-
bound lipoprotein which causes complement resistance [112]. iss was detected in 73% of 
isolates in Study IV. Three patients with a history of hematologic cancer or transplantation 
had septic shock despite a lack of iss in the causing E. coli. But all immunocompetent 
patients that presented with septic shock had a strain in which iss was detected, which 
suggests that iss might be of importance for development of septic shock in 
immunocompetent patients. 
The adhesins, especially pap, were associated with UTI as the mode of infection, while 
isolates from patients with post-prostate biopsy bloodstream infection were low in adhesins, 
had low overall virulence, suggesting that they are normally low-pathogenic isolates and a 
part of the rectal microbiota but cause bloodstream infection when translocated to the 
bloodstream through the biopsy procedure. The prophylactic treatment with ciprofloxacin 
that is commonly administered is unsuccessful due to ciprofloxacin resistance in these strains.   
Sequence types that were associated with post-prostate biopsy BSI were ST131 subclade C1, 
ST131 subclade A, ST648 and ST1193.  
In Study I we saw that prediction of EPE BSI was difficult, and that 20% of cases with EPE 
BSI lacked the three major risk factors and had not been hospitalized in the last year before 
the current episode. Characteristics associated with this group of patients were previously 
healthy females with UTI, caused by an E. coli lacking FQ-resistance and MDR but carrying 
the adhesin pap and the protease pic.  Repeated episodes in the same patient was caused by a 
closely related strain in 15 out of the 16 patients for whom several isolates were available for 
WGS. These are described in the methods section, in a comparison of different typing 
methods that can be applied on WGS data.  
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Table 12. Final multivariable model for association of patient and microbial characteristics with 
septic shock. Table simplified from Study IV. 
Figure 19. cgMLST minimal spanning tree of ESBL-EC from patients with community-onset BSI 
(n=260). Blue nodes are E. coli with iss; Red nodes are E. coli from patients with haematologic 
malignancy or transplantation; Purple are E. coli with iss from patients with haematologic 
malignancy or transplantation. Dark tone for each colour denotes patients with septic shock or death 
within three days. Phylogroups, STs and ST131 clades with more than three isolates are noted. Tree 
scale corresponds to number of allelic differences. Dashed lines are shortened to facilitate 
visualization. 
Iss is clearly differentially distributed among STs: ST131 clade A, ST1193, ST405 and ST648 
generally lack iss (one exception for ST648). An E. coli without iss was never recovered from a patient 
with septic shock if the patient was immunocompetent (i.e. did not have hematologic cancer or 
transplantation.) 
Illustration created with Enterobase GrapeTree. Note: the tree is the same as the thesis front picture 
but coloured differently.  
 No septic shock or 
death ≤3 days 
(n=233) 
Septic shock or 
death ≤3 days 
(n=27) 
Multivariable 
OR (95%CI) P-value 
Hematologic cancer or 
transplantation 
17 (7)  9 (33) 10.8 (3.2-36.6) <0.001 
iss 167 (72) 24 (89)   5.5 (1.3-22.8) 0.019 
Daily living activity ≥2   64 (27) 14 (52)   3.8 (1.4-9.9) 0.007 
UTI or Prostate biopsy 192 (82) 14 (52)   0.3 (0.1-0.9) 0.026 
Multidrug-resistant 150 (64) 10 (37)   0.3 (0.1-0.7) 0.010 
papACGH 101 (43)   4 (15)   0.2 (0.1-0.6) 0.004 
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5 DISCUSSION 
5.1 EMPIRICAL THERAPY FOR SUSPECTED COMMUNITY-ONSET GRAM-
NEGATIVE INFECTION  
Whenever there is a suspicion of a serious bacterial infection in a patient at the emergency 
department, the physician in charge makes an educated guess of the probable nature of the 
causing organism and chooses appropriate empirical treatment to cover those that are 
necessary to cover initially but without causing overuse of broad-spectrum antibiotics. This 
choice is based on a many different facts, the history of the patient, comorbidities, 
presentation, severity of disease, suspected source of infection, travel history, the local 
resistance epidemiology etc. Is it possible to reduce this choice to a simple score and is that 
desirable?  
Scoring systems, such as CRB-65 for pneumonia can be a help for physicians to triage and 
decide the level of care and standardized use of CRB-65 has been shown to improve care 
[155-157]. qSOFA was suggested to identify patients at risk for sepsis, but the sensitivity is 
unfortunately quite low and a better screening tool for sepsis is needed [38, 158, 159]. Scores 
should never be implemented and used singularly, it is always important to remember the 
limitations of the used score and to consider additional factors not included in the score that 
might be important. For example, misuse and misinterpretations of the Centor-criteria for 
tonsillitis have had adverse consequences, despite its great usefulness when applied in a 
correct fashion [160, 161]. However, used cautiously with knowledge and care, application of 
a prediction score for EPE BSI could improve the appropriateness of empirical therapy and 
be of benefit to these patients. 
5.1.1 Development of a prediction score - which predictors to include? 
In Study I we compared the simple Stockholm score with the more complex Utrecht score. 
There have been several other attempts to develop risk scores for EPE, but most of these were 
developed for other patient populations and were not appropriate for the population of 
patients with community-onset suspected gram-negative infection, which we wanted to target 
[60, 61]. The Utrecht score was developed in the Netherlands, which has an epidemiological 
setting concerning ESBL-prevalence similar to Stockholm [59, 153]. In the Rottier study, the 
estimated prevalence of third generation cephalosporin-resistant (3GCR) Enterobacterales 
was 0.4% in the source population and the rate of 3GCR Enterobacterales was 8.3% in BSI. 
In Stockholm, we had 0.59% estimated prevalence in the source population and an ESBL-
production rate in E. coli from BSI of 7-9% during the years of the study.  
We found that for the Swedish setting, the Stockholm score had a higher specificity than the 
Utrecht score. But interestingly, the aim of the authors of the Utrecht score, was to increase 
the specificity and minimize over-treatment compared to the Dutch empirical treatment 
guidelines that were in place at the time. The Dutch guidelines recommended broad-spectrum 
treatment for patients with a prior EPE-positive culture or prior exposure to fluoroquinolone 
or third generation cephalosporin, which gave a sensitivity of 53.9%, a specificity of 79.5% 
and a PPV of 1.0%. With the Utrecht score they obtained 54.3%, 87.2% and 1.7% 
respectively [153]. 
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The Stockholm and Utrecht scores are similar and several of the risk factors included in the 
Utrecht score had an OR with a significant association with EPE BSI in univariate analysis 
also in Study I. A prior EPE-positive culture was the most important contributor in both 
scores, but for the Utrecht score, only prior EPE-positive cultures within one year was 
included. However, in Study I, we saw that the risk of EPE BSI is increased also for patients 
whose latest EPE-positive culture was sampled more than one year previously. The suspected 
source of infection is important for the risk of infection. In both Study I and the Dutch study, 
a suspected UTI is associated with an increased risk and pneumonia with a decreased risk. 
Unfortunately, UTI is so common that including this in an independent way in the score 
severely diminishes the specificity of the Utrecht score, as any patient >70 years of age, with 
UTI and prior antibiotic treatment in the last 2 months will become positive. In Study I, age 
was not linearly associated with risk of EPE BSI. Although antibiotic treatment with agents 
with an impact on the microbiota had a statistically significant association in univariate 
analysis, it was not significant in the multivariable analysis. This caused the low specificity of 
the Utrecht score, especially in the subgroup with suspected UTI, where the specificity of the 
Utrecht score was only 31% compared to 94% for the Stockholm score.  
Prior antibiotic treatment lacked a statistically significant association with an increased risk of 
EPE BSI in the multivariable analysis in Study I and was thus not included in the score  This 
contradicts results of many previous studies in which recent antibiotic treatment (variably 
defined as any antibiotic, fluoroquinolone or cephalosporin, or a composite group of 
antibiotics with selective activity against Gram-negative bacilli) is associated with an 
increased risk of EPE BSI in various populations [52, 59, 162, 163]. It is well known that use 
of antibiotics selects for AMR bacteria, and that sublethal concentrations can induce 
development of resistance [7]. There were several coactive reasons for this result in Study I: 
a prior EPE-positive culture was a very strong predictor, and prior treatment >3 months with 
a microbiota impact agent was strongly related to a prior EPE-positive culture. For 49% of 
the EPE BSI-cases with any prior EPE-positive culture, this culture was a clinical sample 
collected < 3 months (Figure 16). These patients certainly would have been treated with a 
microbiota impact agent at that time and likely also at previous occasions. Recurrent 
infections are common in patients with EPE in clinical samples, which is also clear from a 
recent study by Lindblom et al. [164]. In the group of patients that lacked the three major 
predictors in Study I, prior treatment with a microbiota impacting agent was indeed 
statistically significantly associated with EPE BSI (Multivariable OR 1.9 (95% CI 1.2-3.0) 
p=0.008) but was in this subset of patients too common in both cases (45%) and controls 
(32%) to be useful as a predictor in a score. In conclusion, there is an association between 
prior antibiotic treatment < 3 months and EPE BSI, but this variable should not be used for 
empirical treatment decisions. 
When translating results of risk factor associations into a prediction score, there are several 
pitfalls. First, the balance between sensitivity and specificity is important - what loss in 
specificity is acceptable to increase the sensitivity? Inclusion of predictors with a moderate 
OR but with a high prevalence in both cases and controls decreases specificity. Second, 
although there might be a statistically significant association in the analysis, how robust is 
this result? The result could be caused by for example study information bias and random 
effects. Third, is the predictor a piece of information that is readily available at the time of 
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decision? Fourth, how complex should the score be? A simple score is easy to use (and to 
create), but with a more complex score with weighting of the included predictors it might be 
possible to increase prediction performance.  
The strategy of creating a simple score and aiming at a high specificity, meant that we ended 
up including the two risk factors for EPE which were already well known, a prior positive 
EPE-culture and prior healthcare abroad. These factors many clinicians already consider 
when choosing empirical therapy, but our results strengthen the reasons to follow this 
practice. The third part, prior prostate biopsy, is related to the practice of giving 
ciprofloxacin-prophylaxis during the procedure. The ciprofloxacin-prophylaxis probably is 
efficient for limiting BSI of ciprofloxacin-susceptible isolates but has probably no or very 
limited effect on development of BSI of ciprofloxacin-resistant isolates, which are often 
ESBL-producing. The procedure including prophylaxis is common in many parts of the 
country, but still the extent of the risk increase with prior prostate biopsy might be enhanced 
due to local traditions.  
The complexity of the score could be less of a problem, if sufficient programming skills and 
resources were applied to further development computerized medical records. Scores such as 
this should not be difficult to integrate into the medical records, most included variables 
could be automatically retrieved from the medical records and automatically calculated and 
presented. 
The Utrecht score is currently under prospective validation in a worldwide study (10 
European countries and Japan) called ESBL-PREDICT, according to preliminary results 
presented at the 29th ECCMID conference in 2019 [165]. The present validation cohort 
includes 4,148 community-onset episodes of suspected Gram-negative infection, of which 87 
were cases with third generation cephalosporin-resistant gram-negative bacteria (3GCR-
GNB) BSI (2.1%). The proportion of patients treated with meropenem was 8.6%. 
Interestingly, this is very similar to the proportion in Study I, in which 8% were treated with 
meropenem. The authors report that with application of the score 6.7% of patients would be 
identified as at high risk for 3GCR-GNB BSI and thus require meropenem and they conclude 
that carbapenem treatment could be reduced. However, this conclusion does not consider the 
severity of disease or other indications for carbapenem treatment that might be present. The 
degree of improvement of appropriateness of treatment is not clear from the conference 
abstract either. The results of the future publication of this project will be interesting to 
follow. 
5.1.2 How should the Stockholm score be used in practice? 
Use of the Stockholm score has not been validated prospectively in clinical practice, which 
should be done in a separate population before application of the score is implemented on a 
broad scale. The epidemiology changes over time, and the composition of the population also 
changes. Nevertheless, the results of the studies included in this thesis increase our 
knowledge of important predictors for an increased risk of EPE BSI, which could be of use 
when choosing empirical treatment.  
A strict application of the Stockholm score was evaluated in Study I, where all patients with 
a positive score were given either meropenem or piperacillin-tazobactam and the result was 
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that giving all patients with a positive score meropenem would improve the time to 
appropriate treatment the most. But do all patients with suspected Gram-negative infection 
and a positive score really need carbapenem treatment as empirical therapy? Calculation of 
the score should be performed on all patients with a suspected Gram-negative infection and 
the physician should take the resulting risk for EPE BSI into consideration when choosing 
empirical treatment. However, individualized medicine with differential prescription 
depending on the patient, and which of the predictor in the score that is positive, is strongly 
recommended.  
For which patients is the time to appropriate therapy vital? Clearly, there is evidence of 
improved survival if appropriate therapy is given within a few hours for patients with septic 
shock [166-168]. Thus, for all patients with septic shock, meropenem treatment is 
appropriate, regardless of the result of the score. This is partly to cover EPE, as was seen in 
Study I, the risk for EPE BSI is increased in patients with septic shock, but also to have a 
broad coverage of other causing organisms. In this context it is important to remember that 
the sensitivity of the Stockholm score is only 50%.   
For patients with a milder presentation, sepsis or just bloodstream infection, there is evidence 
that ESBL-production increases healthcare costs and hospitalization duration [48]. An effect 
on survival is less evident, although lack of early targeted therapy (< 4 days) was 
independently associated with 30-day mortality in one study [169]. For these patients the 
indication of meropenem treatment is more relative and the benefit of the patient needs to be 
compared to the risk of selecting for further resistance and a future situation with even higher 
prevalence of carbapenem-resistant bacteria.  
Meropenem should probably be given empirically to patients with any prior EPE BSI, a prior 
EPE-positive clinical culture within 6 months and patients with a positive score and 
immunosuppression. Prior EPE BSI and other recent clinical samples are associated with a 
high risk of EPE BSI and it is thus a recurrent infection. Early appropriate therapy in these 
cases might reduce the time to improvement, development of septic shock and risk of future 
recurring events.  
Patients with a post-prostate biopsy BSI have a high risk of having EPE BSI, but the risk for 
septic shock is low, the patient is often healthy with unaffected daily living activity, and they 
are often caused by low-virulent strains as was seen in Study IV. For these patients, and for 
other patients with a positive Stockholm score that have a mild initial presentation and low 
risk for septic shock, a carbapenem-sparing regime with piperacillin-tazobactam in the high 
dose 4g every 6 hours might be the best choice.  
However, when treating a suspected or verified EPE BSI with piperacillin-tazobactam there 
are several aspects to consider. Studies comparing the outcome of treatment of EPE BSI with 
different antibiotics have come to diverging conclusions. Three studies concluded that 
piperacillin-tazobactam as empirical or definite therapy is a useful alternative to a 
carbapenem [170-172], while the Merino trial by Harris et al. concluded that definite 
treatment of EPE BSI with piperacillin-tazobactam was inferior, and the study was 
discontinued in advance [173]. This study has been criticized for the inferior AST method 
used for determining susceptibility for piperacillin-tazobactam and that almost all mortality 
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was in the group with terminal cancer [174]. AST of piperacillin-tazobactam generally, but 
especially in ESBL-producing isolates is notoriously difficult with all methods. The 
proportion of EPE resistant to piperacillin-tazobactam in Study I was 14.8%. As was seen in 
Study II, rapid disk diffusion is difficult with piperacillin-tazobactam. If one uses 
piperacillin-tazobactam empirically one cannot generally expect to have an AST result for 
this agent until the final AST is performed. Even then, a substantial additional proportion of 
EPE would end up in the area of technical uncertainty (ATU), where there is uncertainty if 
the isolate should be classified as resistant (R) or susceptible with or without increased 
exposure (I/S), regardless if disk diffusion or an MIC-method was used. In conclusion, if one 
decides to use high-dosage of piperacillin-tazobactam as empirical therapy in a patient with a 
positive Stockholm score, the patient’s clinical response should be closely monitored and if 
there is any sign of failure of improvement, the therapy should be changed.  
Cefotaxime in combination with an aminoglycoside, especially amikacin, has been suggested 
as an alternative carbapenem-sparing treatment [171]. However, in the event of an EPE this 
would mean monotherapy with an aminoglycoside, which might result in inadequate 
concentrations at the infection site and is not recommended in infections other than urinary 
tract infections [175-178]. In both Study I and Study IV the rate of resistance to gentamicin 
was 37%. The resistance to amikacin was lower, but data on amikacin-resistance was 
incomplete. WGS-data in Study IV showed that 96% of the gentamicin-resistant isolates had 
at least one gene for an aminoglycoside modifying enzyme with effect on gentamicin: 94% 
carried an aac(3’)-II (aminoglycoside acetyltransferase gene) and 5% carried ant(2’) 
(aminoglycoside adenylyltransferase gene). No phenotypically gentamicin-susceptible 
isolates carried the genes encoding these two enzymes. 
5.2 RAPID DISK DIFFUSION 
5.2.1 Why do inhibition zones change over time? 
The inhibition zones of wild-type isolates increase over time, but the zones of resistant 
isolates decrease. The explanation is that disk diffusion is completely dependent on the 
passive diffusion of the molecules, in contrast to gradient tests, where application of a 
gradient test rapidly creates an antibiotic gradient in the agar. For wild-type isolates the time 
of diffusion of the antibiotic from the paper disk through the agar is most important. During 
the early phases when rapid reading is applied at 4-8 hours, the concentration in the agar at 
the border of growth is still slowly increasing, and the diffusion does not reach an equilibrium 
until after about 12-16 hours [179, 180]. The diffusion rate of an antibiotic depends on 
various molecular properties which explains that some antibiotics have a bigger difference for 
wild-type bacteria between 6 and 18 hour-readings than others [181]. Resistant isolates, on 
the other hand, sometimes have a slower growth due to the burden of resistance that 
decreases fitness [182]. Additionally, in some cases (in Study II mostly seen with 
trimethoprim-sulfamethoxazole and carbapenems) resistant sub-populations and differential 
expression can cause only individual colonies to appear resistant which might be explained 
by a lag-phase so that they initially behave as susceptible isolates and only later start to 
express resistance [77]. These individual colonies are considered when reading 18-hour 
EUCAST disk diffusion but are difficult to see at early reading.  
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5.2.2 Clinical implementation of rapid disk diffusion 
Rapid disk diffusion, which was evaluated in Study II, is a cost-effective way of obtaining 
rapid AST. Other rapid methods are available, of which some are promising, but they are 
comparatively expensive, can only be performed on a few positive blood cultures per day, 
and a limited number of antibiotics [77, 183, 184]. 
When performed directly from positive blood cultures, inhibition zones for E. coli and K. 
pneumoniae are often readable as early as after 4 hours, the bacteria grow faster since they 
are already in growth mode in the blood cultures. To ensure reproducibility and minimize 
errors of interpretation, as standardized a method as possible is necessary. When performed 
directly from positive blood culture bottles, complete standardization of the inoculum is not 
possible since the concentration of bacteria in the bottle varies between 9.1x106 and 3.4x109 
[185]. EUCAST published a validated method with species- and reading time-specific 
breakpoints in November 2018 and added breakpoints for Acinetobacter baumannii in May 
2019 [186]. Although EUCAST suggests that the early reading can be considered a final 
result, if not in the ATU, a reasonable measure to ensure correct AST in bloodstream 
infection is to also perform a standard disk diffusion. This is needed anyway if any result is in 
the ATU and for antibiotics such as trimethoprim-sulfamethoxazole for which there is not yet 
any rapid reading breakpoints established. Considering the results in Study II it is doubtful if 
it will be possible to create useful early breakpoints for this agent. Additionally, in the case of 
a polymicrobial infection that was not recognized at the time of the early reading, errors in 
interpretation can occur due to a mixture of bacteria. It is therefore a sensible precaution to 
warn the clinician that the results are preliminary and will be confirmed.  
The most important task for the rapid AST is to detect resistance to the empirical antibiotic 
treatment the patient received and, in these cases, to report susceptibility for alternative 
treatments so that therapy correction can be performed as early as possible. Treatment de-
escalation for antibiotic stewardship purposes are also an important task for AST, but it is 
probably in many cases more convenient to wait one more day until the AST-results are 
confirmed before de-escalation. 
The many different breakpoints that are assigned for the three reading times 4, 6 and 8 hours, 
and each species are as was seen in Study II, are completely necessary, but this is at the same 
time a challenge for routine laboratories to implement. The EUCAST method requires 
reading of early inhibition zones +/- 5 minutes of the specific incubation time, otherwise to 
re-incubate and read at the next reading time. This time frame is almost impossible to keep in 
a busy routine laboratory. Local adaptations such as a wider ATU that encompasses all the 
ATUs for 4-8 hours is one way to simplify the process and enable breakpoints to be easily 
programmed in the laboratory information systems. The drawback of this approach is that a 
higher proportion of isolates will be in the ATU and not possible to report. In special cases, a 
manual interpretation according to the time- (and species-) specific EUCAST breakpoint 
tables can then be performed. 
For rapid ESBL-detection in third generation cephalosporin-resistant isolates and suspected 
CPE, lateral flow tests for the most common CTX-M and CPE types [29, 187, 188], 
respectively, are probably better options than 6-hour reading of ROSCO ESBL and CPE 
confirmation kits, although further clinical validation of these tests would be valuable, 
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especially if they are to be applied on 4-6 hour cultures. In Study IV, 92% of the isolates 
carried CTX-M-genes which encode enzymes that, according to the manufacturer, are 
included in the lateral flow CTX-M Multi-test (NGbiotech, Guipry, France) [189]. 
5.2.3 Implication of EUCAST new SIR-definitions for future AST-method 
evaluations 
EUCAST changed the definition of the S/I/R-categories on 1 January 2019. The most 
significant change was that of the definition of the “I”-category [68, 190, 191].  
The previous definition (used 2002-2018) was: 
“I - Clinically Intermediate, a microorganism is defined as intermediate by a level of antimicrobial 
agent activity associated with uncertain therapeutic effect. It implies that an infection due to the 
isolate may be appropriately treated in body sites where the drugs are physically concentrated or 
when a high dosage of drug can be used; it also indicates a buffer zone that should prevent small, 
uncontrolled, technical factors from causing major discrepancies in interpretations.” [192]  
The new definition reads:  
“I – Susceptible, Increased exposure*. A microorganism is categorised as “Susceptible, Increased 
exposure” when there is a high likelihood of therapeutic success because exposure to the agent is 
increased by adjusting the dosing regimen or its concentration at the site of infection…. 
*Exposure is a function of how the mode of administration, dose, dosing interval, infusion time, as 
well as distribution and excretion of the antimicrobial agent will influence the infecting organisms at 
the site of infection.” [68] 
This change emphasises the importance of exposure and dosing and is a necessary change to 
accommodate the increasing need to guide antibiotic therapy, and to indicate which agents 
are treatment alternatives when treatment success is probable when high exposure is achieved 
despite the presence of resistance mechanisms. At the same time the introduction of a new 
concept of ATU, area of technical uncertainty, poses greater demands on the laboratories for 
quality assurance of the AST methods used, and EUCAST recommends individualized 
interpretations on results in the ATU. However, the removal of the buffer zone interpretation 
of the I-category and the new concept ATU, complicates comparisons of AST methods. 
Previously any result that included an I-result was considered a minor error. What comprises 
a minor error with the new SIR-definitions? When there is no I-category, all discrepancies are 
either VMEs or MEs. Should discrepancies that include any result that fall into ATU be 
considered minor errors? Since the I-category now is considered Susceptible, increased 
exposure – should a discrepancy of I with new method and R with reference method be 
considered a VME instead of a minor error? This is especially important for agent-microbe 
combinations where the entire wildtype now is categorized as “I”. There is a need for 
EUCAST to acknowledge these consequences of the change and for the regulatory agency 
European Medicines Agency to clarify how to handle this issue. It has hitherto not been 
addressed in the currently available documents about the SIR-definition change on the 
EUCAST web page, or by ISO [192]. The ISO Standard 20776-2:2007 is currently under 
revision [193].  
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5.3 IS THE GLOBAL NDM-1 EXPANSION DRIVEN BY SUCCESSFUL CLONES 
OR PROMISCIOUS PLASMIDS? 
NDM-1 has spread rapidly since the first observation in 2008 [154] and the early years of the 
expansion when Study III was published in 2012. NDM has become the second most 
common carbapenemase in Sweden, after OXA-48, although the total number of CPE is still 
low, 144 reported cases in 2018 out of which 31% were clinical infections. Approximately 
40% of isolates carried NDM and 50% carried OXA-48 [194]. According to the SMART 
global surveillance study conducted in 2008-2014, blaNDM was the third most common 
carbapenemase-gene comprising 19% of carbapenemase-producing isolates, compared to 
53% for KPC and 20% of OXA-48 [18, 195]. The study showed large regional differences, 
with KPC being most prevalent in North America and Latin America, OXA-48 in Africa and 
the Middle East, and NDM in Asia and the South Pacific. Europe has a mixture of mainly 
KPC, and OXA-48, but also VIM and NDM [195]. As most (73%) of reported cases of CPE 
in Sweden are identified in targeted screening at admission to hospital of patients with a 
history of hospitalization abroad [194], the epidemiology of CPE in Sweden mainly reflects 
the international travel and healthcare patterns of Swedish patients.  
In a thorough review of NDM-carbapenemase epidemiology published in April 2019, Wu et 
al. summarizes the current knowledge which has greatly expanded since Study III was 
published in 2012 [18]. Although the origin of NDM is still not completely defined, there are 
indications that blaNDM-1 originated in Acinetobacter species and is a chimera of the 
aminoglycoside resistance gene aphA6 and a pre-existing MBL-gene [196]. blaNDM genes 
have been found in a wide range of Gram-negative bacilli, both mainly environmental species 
and common human pathogens, including Pseudomonas aeruginosa, Acinetobacter 
baumannii and many different species of the Enterobacterales, but K. pneumoniae and E. coli 
are the most common. In support of our results from Study III, there is still no clearly 
predominant clone of NDM-positive K. pneumoniae on a global scale and NDM is found in 
many different sequence types. The most common are ST14, ST11 and ST147, which were 
also observed in Study III. Other frequently reported types are ST15 and ST23 (mainly 
China). The situation is the same for E. coli, where NDM is found in diverse sequence types. 
The genes are usually located on plasmids and 20 different plasmid replicon types have been 
associated with blaNDM in Enterobacteriaceae, including broad-range plasmids IncA/C and 
IncL/M and the narrow-host-range plasmids IncX3 (hitherto only seen in the 
Enterobacteriaceae), IncFIA, IncFIB and IncFII [18]. This indicates that horizontal transfer 
is the most important way for the spread of blaNDM and that it is mediated by multiple 
plasmids with different properties. Nevertheless, local clonal spread of NDM-producing K. 
pneumoniae in hospital settings is a concern [18, 33, 197], which means that intervention 
strategies must be directed both at minimizing direct transmission and horizontal transfer. 
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5.4 POSSIBLE TREATMENT TARGETS IN SEPSIS - HOST RESPONSE AND 
MICROBE VIRULENCE 
With increasing levels of resistance that threaten to make effective antibiotics useless, the 
search for new classes of traditional antibiotics for Gram-negative bacteria has intensified in 
the last decades but have unfortunately largely failed (with a few exceptions, e.g. the 
promising new class of siderophore cephalosporins (cefiderocol) [27]). There is thus a great 
need to search for alternative treatment strategies. Clearly, both the host response and 
microbial virulence influences infection and severity of disease, and thus are potential targets 
for future sepsis treatment.  
The pathogenesis in sepsis is complex and characterized by a dysregulated immune response 
[38].  Several studies show that the type of dysregulation differs between individuals and the 
risk of dying of sepsis is associated with human genetic predisposition. As was seen in Study 
IV, it is well known that patients with immunosuppression due to hematologic malignancy 
and transplantation are at higher risk of infection, septic shock and mortality. However, also 
in patients without acquired immune suppression, there are important differences regarding 
immune response between individuals. A sepsis transcriptomics study identified two types of 
patients with distinct sepsis response signatures (SRS1 and SRS2) based on global genetic 
expression, the SRS1 group that was characterized by immunosuppression was associated 
with higher early mortality than SRS2 [198]. Further studies showed that patients could be 
classified into four groups based on different gene expression patterns [40]. A phase 1b 
clinical trial testing safety issues for an immunomodulatory therapy in patients with the 
immunosuppressed SRS1 phenotype was published in 2019. This therapy targets an immune 
checkpoint pathway, the programmed cell death protein-1 (PD-1) / programmed cell death-
ligand 1 (PD-L1) pathway [199]. The pathway regulates the immune response under normal 
conditions. In certain cancer cells and in sepsis-induced dysregulated immunosuppression an 
upregulation of this pathway is seen. The upregulation causes T-cell inhibition. Monoclonal 
antibodies that block PD1 and PD-L1 is an effective cancer treatment and could also be 
effective in reducing the immunosuppression in sepsis and is a promising new treatment in 
the group of patients with sepsis characterized by immunosuppression. The Phase 1b study 
showed promising results, with no sign of a cytokine storm, an overstimulation of the 
immune response, which is one of the concerns with such therapies.   
Virulence factors have been proposed as promising targets for new adjuvant infection 
treatments [6, 200]. The potential advantages of targeting virulence factors are several, 
including low impact on host commensal flora, possibly less evolutionary pressure for 
development of resistance with traditional antibiotics, rapid inactivation of targets [200]. 
Disadvantages include that they may require combination therapy for multiple virulence 
factors, empirical treatment is difficult due to species or strains-specific virulence factors and 
this requires rapid diagnostic methods, the microbes might not be killed and may persist and 
cause damage when the treatment is stopped. They may be less efficient compared to 
antibiotics, but adjuvant effects could possibly be achieved. Development of anti-virulence 
drugs for sepsis requires deep understanding of the sepsis pathogenesis and which roles 
different virulence factors play for the course of the infection [200]. Ideally blocking of the 
target would not affect the survival so that the overall selective pressure would not direct 
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bacterial evolution. Good targets are excreted or exposed on the surface of the microbe. 
Studies like Study IV is a first step for identification of potential important targets.  
In Study IV we found a clear association of adhesion factors with a urinary tract infection 
source in patients with community-onset BSI caused by ESBL-EC, which was expected since 
adhesion factors are of well-known importance for UTI and pyelonephritis [116].  The tip of 
the E. coli adhesin type 1 fimbriae, FimH, is the target of two compounds in preclinical drug 
development phase, mAb926 and Compound 22 [200]. These agents were effective in mouse 
UTI models. The monoclonal antibody mAb926 prevented ExPEC attachment to epithelial 
cells and detached biofilms, while the biarylmannoside receptor analogue Compound 22 
prevented UTIs and potentiated the effect of prophylactic antibiotic treatment. Despite their 
possible benefit in or preventing UTIs or treatment at an early stage of infection, since type 1 
fimbriae are important for adhesion to the urinary epithelium, anti-virulence drugs targeting 
this virulence factor are not likely useful in sepsis since the E. coli are already in the blood 
and other virulence factors are more important for the course of sepsis.  
An association with septic shock was found for the virulence factor iss, increased serum 
survival in Study IV. This virulence factor has some properties that are favourable for an 
anti-virulence target. Iss, the product of iss, is a lipoprotein located on the outer membrane of 
E. coli [201]. iss has primarily been studied as a virulence factor associated with avian 
colibacillosis, which is a systemic infection with E. coli in birds caused by APEC, a subset of 
ExPEC [201-205]. iss was associated with a 20-fold increase in complement resistance and a 
100-fold increase in virulence toward 1-day old chicks [112]. Monoclonal antibodies to Iss 
were developed and used to ascertain the location of Iss on the outer membrane. Iss was also 
evaluated as an antigen for immunization for colibacillosis in poultry and showed a clear 
protective effect [204]. One concern about the usefulness of monoclonal antibodies or 
immunization based on Iss is its similarity, which causes cross-reactivity, with the product of 
the λ phage derived gene bor, which has a 90% similarity to iss. The bor gene encodes the 
lipoprotein Bor that is found on the outer membrane of these isolates and is common both in 
avian commensals and pathogens [201]. However, this similarity does not necessarily 
diminish the potential of Iss as a target for anti-virulence treatment in human sepsis. Bor was 
mainly found in E. coli that were of bovine or avian origin and less than 10% of human 
isolates carried Bor [112]. Bor was also uncommon in the phylogroup B2 [112], which is 
responsible for 50% of bloodstream infections in Sweden [94]. Additionally, Bor also confers 
serum-resistance, albeit at a lower level [112], so this cross-reactivity would probably not 
interfere negatively with a potential anti-virulence agent. Combined, these prior studies 
support that the cell-membrane bound Iss has a potential as a target for a monoclonal 
antibody that could be used as an adjuvant in sepsis-treatment to limit the severity of sepsis. 
Further studies on the importance of iss and effect of blockade with monoclonal antibodies in 
various virulence and sepsis models should be performed.   
In conclusion, both immunomodulatory pathways and microbe virulence genes are promising 
new targets for adjuvant treatment in sepsis. However, since there is a great interindividual 
variation and variation in microbial virulence factors, individualized treatment requires new 
diagnostic methods that can determine the immune response pattern and determine which 
microbial virulence factors that should be targeted in each patient. 
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6 CONCLUSIONS 
 
• Patients with a prior EPE-positive culture, prior healthcare abroad or a prior prostate 
biopsy with suspected community-onset infection are at risk of having EPE BSI and 
empiric therapy covering EPE should be considered for these patients at admission. 
• Any finding of a prior EPE-positive culture is associated with an increased risk for 
EPE BSI, but for a recent culture taken within 6 months the increased risk is more 
pronounced.   
• Risk-scoring systems for AMR bacteria are dependent on local epidemiology and 
must be locally validated before implementation. 
• Prediction of EPE BSI is difficult, 50% of patients with EPE BSI lack the three 
principal predictors and rapid diagnostic methods that include antimicrobial 
susceptibility testing are important. 
• Rapid disk diffusion gives reliable results for the most important agents when adapted 
breakpoints are used.  
• For rapid confirmation of ESBL- and carbapenemase-production rapid disk diffusion 
is less useful and other methods should be considered. 
• blaNDM-1 is found in diverse sequence types in K. pneumoniae. The global spread of 
blaNDM-1 is to a large part caused by horisontal transfer of plasmids and there are no 
clearly dominant clones on a global scale. Nevertheless, both intra- and inter-hospital 
transmission occur and implementation of appropriate infection control measures are 
necessary to limit further expansion of these strains for which there are very few 
treatment options.  
• The fluoroquinolone-resistant high-risk clone ST131 subclade C2 dominates in 
community-onset BSI caused by ESBL-producing E. coli in Stockholm. 
• The E. coli virulence factor increased serum survival, iss, which causes complement 
resistance, is associated with septic shock and might be important for the severity of 
disease in immunocompetent patients. 
• Post-prostate biopsy EPE BSI is often caused by low-virulent strains and septic shock 
is uncommon. Carbapenem-sparing treatment with coverage of EPE might be 
considered in these patients. 
• Repeated episodes of EPE BSI in the same patient is often caused by a closely related 
strain.   
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7 FUTURE PERSPECTIVES 
Prediction and individualized sepsis-treatment 
The Stockholm score has the potential to improve the appropriateness of empirical treatment 
without a great increase in unnecessary treatments. However, implementation of the score 
should be accompanied by prospective validation to ensure the usefulness in clinical practice. 
With current medical journals it is time-consuming work for doctors at emergency 
departments to look for prior cultures and other important information. Time is limited in 
busy emergency departments. Improved modernized medical records where data can be 
easily extracted by computerized algorithms and automatically give the risk score and 
predicted susceptibility patterns based on relevant prior cultures could further increase the 
benefit of the score and facilitate validation [206].     
This could favourably be combined with immunological tests, to determine patient’s type of 
sepsis immune response, and deep learning (see below) to obtain a truly individualized sepsis 
treatment with both immunotherapy and appropriate antibiotic treatment. 
Implementation of EUCAST direct RAST 
Rapid phenotypic testing is important. The EUCAST Rapid AST disk diffusion method 
directly from positive blood cultures is a cost-effective, flexible method for rapid AST that 
will be implemented at Karolinska University Laboratory within the coming year. In addition 
to this, for selected, severely ill patients, ultra-rapid methods for species identification and 
AST with results within a few hours would be beneficial. There are various methods in 
development, based on nanotechnology, microfluidic methods, time-lapse microscopy, single 
cell imaging and flow cytometry [77, 86].   
Oxford Nanopore in diagnostics  
The new method Oxford Nanopore is still too expensive to be useful for routine diagnostics, 
but prices fall quickly and there is a high potential for clinical application of this method. 
Oxford Nanopore has been suggested for prediction of AST through a combination of 
sequence types and resistance genes [207]. Additionally, this method could shorten the time 
for infection control and enable early detection of nosocomial transmissions within a few 
days, compared to the several weeks it takes today. This would be especially useful if 
software that integrate the results of phylogenetic analysis such as cgMLST and information 
on patient movement and wards, were used. Combining these data in one software would 
produce a potent tool for early detection of hospital transmission events and enable early 
intervention. To accomplish this, high competence in computer software programming and 
bioinformatics combined with knowledge on infection control needs are necessary. 
Studies on complement resistance and iss 
The iss-gene was associated with septic shock, especially with immunocompetent patients. 
This warrants further investigations to see if the finding can be repeated in a larger patient 
material and to find out if the increased severity is mediated through the iss-gene, or if it is 
mediated through an unknown associated mechanism. It would be interesting to study 
complement-resistance of the isolates in Study IV, see if there is an association of 
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complement resistance both to septic shock and to iss in this collection and if this 
complement resistance could be inhibited with a monoclonal antibody. 
Potential applications of deep learning in microbiology 
Deep learning, a subset of artificial intelligence and machine learning, is a process of 
exposing multi-layered artificial neural networks to vast amounts of data, thereby training the 
networks to perform certain tasks [208]. The computational power of these kinds of neural 
networks has increased rapidly in the last decade. Deep learning is especially useful for 
finding patterns in images and other complex datasets and has already been widely used for 
analyses in radiology and pathology. However, the methods are hitherto not widely applied 
for microbiology despite the high potential. A PubMed search in October 2019 for deep 
learning AND radiology gave 1,138 hits; deep learning AND pathology 751 hits but deep 
learning AND (Microbiology OR antimicrobial OR antibiotic) only 132 hits. Training of 
artificial neural networks involves exposing them for a high number of annotated 
images/datasets (labelled with the “true” result as defined by a reference method), with this 
the neural networks find patterns and improve performance the more datasets they are 
provided with.   
There are several potential applications of deep learning in microbiology related to the studies 
described in this thesis. As deep learning is especially suitable for image pattern recognition, 
it could be used on the digital images obtained by the Kiestra BD system, for facilitating the 
manual digital reading performed today. With proper training it would be useful for 
identifying possible pathogens and typical normal microbiota findings. In antimicrobial 
susceptibility testing with disk diffusion it could provide a highly standardized, rapid and 
accurate reading of inhibition zones.   
Deep learning could be applied to clinical prediction models in combination with modern 
medical records where relevant data could be automatically extracted. Then the risk score and 
suggested therapy could be presented. The deep learning system could continuously adapt 
and improve the prediction model over time, although this would require repeated validation. 
However, proper consideration for patient integrity and data protection must be ensured if 
these methods are implemented. 
As a continuation of the study of the influence of microbiological virulence for septic shock, 
deep learning in combination with Genome Wide Association Studies (GWAS) could be 
applied. In Study IV 108 genes were studied but with this method the neural networks could 
look for patterns of association with septic shock in the entire genome, combined with a high 
number of clinical parameters and results from immunological tests and expression data. 
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8 SAMMANFATTNING PÅ SVENSKA 
Antibiotikaresistens är ett ökande problem, och särskilt resistensförekomst hos tarmbakterier, 
eftersom de blir mycket svåra att behandla. Utveckling av antibiotikaresistens är en naturlig 
evolutionär process där antibiotikaproducerande miljöbakterier som funnits i miljontals år 
och har utvecklat resistensgener för att skydda sig själva, nu överför dessa resistensgener till 
de bakterier som orsakar infektioner hos människor. Antibiotika utsätter bakterierna för ett 
evolutionärt tryck, vilket ger de resistenta bakterierna en fördel varmed dessa ökar i antal. 
Antibiotikaresistenta bakterier är ett hot mot global folkhälsa. I de flesta länder i världen är 
resistensfrekvensen mycket högre än i Sverige.  
Escherichia coli, som tillhör tarmbakteriegruppen Enterobacterales, är en av de viktigaste 
sjukdomsframkallande bakterierna. Det finns många olika sorters E. coli. För det mesta utgör 
de en viktig del av en frisk tarmflora men vissa är diarré-framkallande och orsakar bl.a. turist-
diarré. Andra typer av E. coli kan orsaka urinvägsinfektion och blodförgiftning. Dessa 
bakterier kallas ExPEC, extra-intestinala patogena E. coli, vilka förekommer i tarmfloran och 
orsakar infektion när de hamnar i andra organ. ExPEC bär många olika virulensegenskaper 
som bl.a. underlättar för bakterien att fastna i urinvägarna. Det kallas bakteriemi när 
bakterierna från en infektionshärd når blodet, och detta kan leda till blodförgiftning. E coli är 
den vanligaste orsaken till bakteriemi och urinvägsinfektion är för E. coli den vanligaste 
ursprungshärden. Vid blodförgiftning är det viktigt med snabb behandlingsstart med effektiva 
antibiotika. Antibiotikabehandling som startas innan bakterieodlings-svar finns tillgängliga 
kallas empirisk behandling. Den vanligaste empiriska behandlingen i Sverige är cefotaxim.  
Alla typer av E. coli kan förvärva resistensmekanismer mot antibiotika. Den vanligaste 
resistensmekanismen hos E. coli är att de bildar ett enzym som hydrolyserar (bryter ner) 
antibiotika. Det enzym som ger resistens mot cefotaxim kallas extended-spectrum beta-
lactamase (ESBL). Vissa enzym påverkar också karbapenemer och kallas ESBLCARBA. Genen 
som kodar för dessa enzym sitter på en plasmid, ett cirkulärt DNA-fragment, som bakterier 
lätt kan överföra mellan två bakterier av samma eller olika art, vilket underlättar spridning. 
Under början av 2000-talet ökade andelen med cefotaxim-resistens bland fynd av E. coli i 
blododlingar provtagna på Karolinska mycket snabbt, från 3% år 2005 till 10% år 2012.   
Denna bok handlar om patienter som drabbas av bakteriemi och blodförgiftning med ESBL-
bildande bakterier. På grund av resistensen fungerar inte cefotaxim, den vanliga empiriska 
antibiotikabehandlingen. Fel behandling innebär risk för längre vårdtider och ökad dödlighet. 
Målsättningen har varit att förbättra behandlingen av patienter med blodförgiftning orsakad 
av ESBL-bildande bakterier på olika sätt: tidig identifiering av högriskpatienter på 
akutmottagningen, snabb resistensbestämning samt ökad förståelse av resistensspridning och 
virulensfaktorers påverkan på svårighetsgraden av sjukdomen. 
I Studie I var målsättningen att skapa ett enkelt system för risk-klassificering för att 
identifiera vilka patienter som behöver anpassad empirisk antibiotikabehandling med effekt 
även mot ESBL-bildande bakterier. Riskfaktorer för bakteriemi med dessa bakterier 
undersöktes därför i en retrospektiv fall-kontroll studie med 277 fall och 400 kontroller. Två 
olika risk-klassificeringssystem jämfördes. Studien visade att de tre starkaste riskfaktorerna 
var fynd av ESBL-bildande bakterier i en tidigare odling (särskilt fynd inom de senaste 6 
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månaderna), prostatabiopsi inom en månad och sjukvård utomlands senaste halvåret. Av 
patienterna med bakteriemi orsakad av ESBL-bildande bakterier hade 50% någon av dessa 
tre riskfaktorer, medan det var svårt att förutspå risken hos övriga patienter. Resultatet 
understryker vikten av snabb diagnostik och resistensbestämning.  
Målsättningen med Studie II var därför att utvärdera en snabb resistensbestämningsmetod. 
Diskdiffusion är en vanlig metod för resistensbestämning. En bakteriesuspension stryks på en 
agaryta varefter antibiotikalappar läggs på och antibiotikan diffunderar passivt i agarn. 
Hämningszonens storlek avgör om bakterien är känslig eller resistent. Vanligtvis avläses 
zonerna nästkommande dag. I studien undersöktes zonavläsning efter kortare tid (6 timmars 
inkubation) på 128 E. coli och K. pneumoniae med resistens för viktiga antibiotika och 
jämfördes med normal (18 timmars) inkubation. Studien visade att zonstorlekarna var 
annorlunda vid tidig avläsning, samt att skillnaden mellan resistenta och känsliga isolat var 
mindre. Men 6-timmarsavläsning var ändå en tillförlitlig metod om man anpassade gränserna 
för vad som rapporterades som känsligt respektive resistent. Detta innebär att cefotaxim-
resistens kan påvisas en dag tidigare, och den empiriska behandlingen kan vid behov ändras.  
En god förståelse av resistensgeners spridningsvägar är viktigt för utveckling av effektiva 
strategier för att motverka spridning. I Studie III undersöktes 39 K. pneumoniae av typen 
ESBLCARBA från Indien, Storbritannien och Sverige. Dessa bildade ett karbapenemas vid 
namn NDM, New Dehli metallo-beta-laktamas, som är kopplad till multiresistens och få 
behandlingsalternativ finns. Studien visade att NDM fanns hos många olika s.k. sekvenstyper 
av K. pneumoniae och på många olika typer av plasmider. Slutsatsen var att resistensmekan-
ismen främst spreds genom plasmidöverföring, men samtidigt förekom lokala utbrott. 
Bakteriemi kompliceras ofta av blodförgiftning (sepsis) och septisk chock vilket medför hög 
risk för död. Med ökande resistensförekomst som gör vanliga antibiotika obrukbara behöver 
efterforskningar göras för att hitta nya angreppspunkter för läkemedel, t.ex. virulensfaktorer. 
För att identifiera lämpliga mål krävs en korrekt förståelse av virulensfaktorers betydelse för 
sjukdomsuppkomst och förlopp vid blodförgiftning. Målsättningen för Studie IV var att 
undersöka den relativa betydelsen av patientfaktorer och bakteriefaktorer för uppkomst av 
septisk chock hos patienter med blodförgiftning orsakad av ESBL-bildande E. coli. Totalt 
278 ESBL-bildande E. coli från 260 patienter med blodförgiftning (vilka ingick i Studie I) 
undersöktes med helgenomsekvensering för att kartlägga bakteriernas arvsmassa, DNA-
sekvens. Resultaten visade att virulensgenen iss (increased serum survival), som medför 
resistens mot immunförsvarets komplementsystem, var associerad med septisk chock, särskilt 
hos patienter utan hematologisk cancer eller transplantation. 
Sammantaget har studierna i denna avhandling visat att behandling av patienter med 
bakteriemi orsakad av ESBL-bildande bakterier kan förbättras på flera olika sätt. Många 
patienter med hög risk för detta kan identifieras redan på akutmottagningen, och få anpassad 
empirisk behandling. Inte alla patienter hittas på så vis, men med snabb diskdiffusion kan 
tiden till resistensbeskedet förkortas avsevärt och terapin kan tidigt korrigeras. NDM 
produceras av olika sekvenstyper av K. pneumoniae och horisontell plasmidöverföring är en 
viktig förklaring till den oroande spridningen av dessa multiresistenta bakterier. Virulens-
faktorn iss var associerad med septisk chock hos patienter med blodförgiftning med E. coli 
ESBL och denna gen kan kanske användas som ett mål för framtida anti-virulens-behandling.   
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